AU2005200019A1 - Novel mitogenic regulators - Google Patents

Description

AUSTRALIA

Patents Act 1990 EMORY UNIVERSITY COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Novel mitogenic regulators The following statement is a full description of this invention including the best method of performing it known to us:- NOVEL MITOGENIC REGULATORS This is a divisional application from Australia Patent Application No 1911800, the entire contents of which are herein incorporated by reference.

The U. S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of National Institutes of Health grants HL38206 and HL58000.

TECHNICAL FIELD The present invention relates to the field of normal and abnormal cell growth, in particular mitogenic regulation.

The present invention provides the following: nucleotide sequences encoding for the production of enzymes that are mitogenic regulators; amino acid sequences of these enzymes; vectors containing these nucleotide sequences; methods for transfecting cells with vectors that produce these enzymes; transfected cells; methods for administering these transfected cells to animals to induce tumor formation; and antibodies to these enzymes that are useful for detecting and measuring levels of these enzymes, and for binding to cells possessing extracellular epitopes of these enzymes.

BACKGROUND OF THE INVENTION Reactive oxygen intermediates (ROI) are partial reduction products of oxygen: 1 electron reduces 02 to form superoxide and 2 electrons reduce 02 to form hydrogen peroxide (H 2 0 2 ROI are generated as a byproduct of aerobic metabolism and by toxicological mechanisms. There is growing evidence for regulated enzymatic generation of 02- and its conversion to H 2 0 2 in a variety of cells. The conversion of 02 to H 2 0 2 occurs spontaneously, but is markedly accelerated by superoxide dismutase (SOD). High levels of ROI are associated with damage to biomolecules such as DNA, biomembranes and proteins. Recent evidence indicates generation of ROI under WO 00/28031 PCT/US99/26592 2 normal cellular conditions and points to signaling roles for 02 and

H

2 0 2 Several biological systems generate reactive oxygen. Phagocytic cells such as neutrophils generate large quantities of ROI as part of their battery of bactericidal mechanisms. Exposure of neutrophils to bacteria or to various soluble mediators such as formyl-Met-Leu-Phe or phorbol esters activates a massive consumption of oxygen, termed the respiratory burst, to initially generate superoxide, with secondary generation of H202, HOCI and hydroxyl radical. The enzyme responsible for this oxygen consumption is the respiratory burst oxidase (nicotinamide adenine dinucleotide phosphate-reduced form (NADPH) oxidase).

There is growing evidence for the generation of ROI by non-phagocytic cells, particularly in situations related to cell proliferation. Significant generation of H 2 0 2 O2, or both have been noted in some cell types. Fibroblasts and human endothelial cells show increased release of superoxide in response to cytokines such as interleukin-1 or tumor necrosis factor (TNF) (Meier et al. (1989) Biochem J. 263, 539-545.; Matsubara et al. (1986) J. Immun. 137, 3295-3298). Rastransformed fibroblasts show increased superoxide release compared with control fibroblasts (Irani, et al. (1997) Science 275, 1649-1652). Rat vascular smooth muscle cells show increased

H

2 0 2 release in response to PDGF (Sundaresan et al.

(1995) Science 270, 296-299) and angiotensin II (Griendling et al. (1994) Circ. Res. 74, 1141-1148; Fukui et al. (1997) Circ.

Res. 80, 45-51; Ushio-Fukai et al. (1996) J. Biol. Chem. 271, 23317-23321), and H202 in these cells is associated with increased proliferation rate. The occurrence of ROI in a variety of cell types is summarized in Table 1 (adapted from Burdon, R. (1995) Free Radical Biol. Med. 18, 775-794).

WO 00/28031 PCT/US99/26592 3 Table 1 Superoxide Hydrogen Peroxide human fibroblasts Balb/3T3 cells human endothelial cells rat pancreatic islet cells human/rat smooth muscle cells murine keratinocytes human fat cells rabbit chondrocytes human osteocytes human tumor cells BHK-21 cells fat cells, 3T3 LI cells human colonic epithelial cells ROI generated by the neutrophil have a cytotoxic function. While ROI are normally directed at the invading microbe, ROI can also induce tissue damage in inflammatory conditions such as arthritis, shock, lung disease, and inflammatory bowel disease) or may be involved in tumor initiation or promotion, due to damaging effects on DNA.

Nathan (Szatrowski et al. (1991) Cane. Res. 51, 794-798) proposed that the generation of ROI in tumor cells may contribute to the hypermutability seen in tumors, and may therefore contribute to tumor heterogeneity, invasion and metastasis.

In addition to cytotoxic and mutagenic roles, ROI have ideal properties as signal molecules: 1) they are generated in a controlled manner in response to upstream signals; 2) the signal can be terminated by rapid metabolism of 0O and H202 by SOD and catalase/peroxidases; 3) they elicit downstream effects on target molecules, redox-sensitive regulatory proteins such as NF kappa B and AP-1 (Schreck et al. (1991) EMBO J.

2247-2258; Schmidt et al. (1995) Chemistry Biology 2, 13-22). Oxidants such as 02 and H 2 0 2 have a relatively well defined signaling role in bacteria, operating via the SoxII regulon to regulate transcription.

ROI appear to have a direct role in regulating cell division, and may function as mitogenic signals in pathological conditions related to growth. These conditions include cancer and cardiovascular disease. 02- is generated in endothelial cells WO 00/28031 PCT/US99/26592 4 in response to cytokines, and might play a role in angiogenesis (Matsubara et al. (1986) J. Immun. 137, 3295-3298). 02- and H202 are also proposed to function as "life-signals", preventing cells from undergoing apoptosis (Matsubara et al. (1986) J.

Immun. 137, 3295-3298). As discussed above, many cells respond to growth factors platelet derived growth factor (PDGF), epidermal derived growth factor (EGF), angiotensin II, and various cytokines) with both increased production of 02 /H202 and increased proliferation. Inhibition of ROI generation prevents the mitogenic response. Exposure to exogenously generated 02, and H202 results in an increase in cell proliferation. A partial list of responsive cell types is shown below in Table 2 (adapted from Burdon, R. (1995) Free Radical Biol. Med. 18, 775-794).

Table 2 Superoxide Hydrogen peroxide human, hamster fibroblasts mouse osteoblastic cells Balb/3T3 cells Balb/3T3 cells human histiocytic leukemia rat, hamster fibroblasts mouse epidermal cells human smooth muscle cells rat colonic epithelial cells rat vascular smooth muscle cells rat vascular smooth muscle cells While non-transformed cells can respond to growth factors and cytokines with the production of ROI, tumor cells appear to produce ROI in an uncontrolled manner. A series of human tumor cells produced large amounts of hydrogen peroxide compared with non-tumor cells (Szatrowski et al.

(1991) Canc. Res. 51, 794-798). Ras-transformed NIH 3T3 cells generated elevated amounts of superoxide, and inhibition of superoxide generation by several mechanisms resulted in a reversion to a "normal" growth phenotype.

02- has been implicated in maintenance of the transformed phenotype in cancer cells including melanoma, breast carcinoma, fibrosarcoma, and virally transformed tumor WO 00/28031 PCT/US99/26592 cells. Decreased levels of the manganese form of SOD (MnSOD) have been measured in cancer cells and in vitrotransformed cell lines, predicting increased 0 2 levels (Burdon, R. (1995) Free Radical Biol. Med. 18, 775-794). MnSOD is encoded on chromosome 6q25 which is very often lost in melanoma. Overexpression of MnSOD in melanoma and other cancer cells (Church et al. (1993) Proc. of Natl. Acad. Sci. 3113-3117; Femandez-Pol et al. (1982) Canc. Res. 42, 609-617; Yan et al. (1996) Canc. Res. 56, 2864-2871) resulted in suppression of the transformed phenotype.

ROI are implicated in growth of vascular smooth muscle associated with hypertension, atherosclerosis, and restenosis after angioplasty. O0' generation is seen in rabbit aortic adventitia (Pagano et al. (1997) Proc. Natl. Acad. Sci.

94, 14483-14488). Vascular endothelial cells release 02 in response to cytokines (Matsubara et al. (1986) J. Immun. 137, 3295-3298). 02- is generated by aortic smooth muscle cells in culture, and increased 0 2 generation is stimulated by angiotensin II which also induces cell hypertrophy. In a rat model system, infusion of angiotensin II leads to hypertension as well as increased 02; generation in subsequently isolated aortic tissue (Ushio-Fukai et al. (1996) J. Biol. Chem. 271, 23317- 23321.; Yu et al. (1997) J. Biol. Chem. 272, 27288-27294).

Intravenous infusion of a form of SOD that localizes to the vasculature or an infusion of an 02 scavenger prevented angiotensin II induced hypertension and inhibited ROI generation (Fukui et al. (1997) Circ. Res. 80, 45-51).

The neutrophil NADPH oxidase, also known as phagocyte respiratory burst oxidase, provides a paradigm for the study of the specialized enzymatic ROI-generating system.

This extensively studied enzyme oxidizes NADPH and reduces oxygen to form 02-. NADPH oxidase consists of multiple proteins and is regulated by assembly of cytosolic and membrane components. The catalytic moiety consists of flavocytochrome an integral plasma membrane enzyme comprised of two components: gp91phox (gp refers to WO 00/28031 PCT/JS99/26592 6 glycoprotein; phox is an abbreviation of the words phagocyte and oxidase) and p22phox (p refers to protein). gp91phox contains 1 flavin adenine dinucleotide (FAD) and 2 hemes as well as the NADPH binding site. p22phox has a C-terminal proline-rich sequence which serves as a binding site for cytosolic regulatory proteins. The two cytochrome subunits, gp91phox and p22phox appear to stabilize one another, since the genetic absence of either subunit, as in the inherited disorder chronic granulomatous disease (CGD), results in the absence of the partner subunit (Yu et al. (1997) J. Biol. Chem. 272, r 27288-27294). Essential cytosolic proteins include p47phox, p67phox and the small GTPase Rac, of which there are two isoforms. p47phox and p67phox both contain

SH

3 regions and proline-rich regions which participate in protein interactions governing assembly of the oxidase components during activation. The neutrophil enzyme is regulated in response to bacterial phagocytosis or chemotactic signals by phosphorylation of p47phox, and perhaps other components, as well as by guanine nucleotide exchange to activate the GTPbinding protein Rac.

The origin of ROI in non-phagocytic tissues is unproven, but the occurrence of phagocyte oxidase components has been evaluated in several systems by immunochemical methods, Northern blots and reverse transcriptase-polymerase chain reaction (RT-PCR). The message for p22phox is expressed widely, as is that for Racl. Several cell types that are capable of 02 generation have been demonstrated to contain all of the phox components including gp91phox, as summarized below in Table 3. These cell types include endothelial cells, aortic adventitia and lymphocytes.

WO 00/28031 PCT/US99/26592 7 Table 3 Tissue gp91phox p22phox p47phox p67phox neutrophil +1.2 +1.2 +1.2 +1.2 aortic adventitia +1 +1 1 +1 lymphocytes +2 +2 +1.2 +1.2 endothelial cells +2 +2 +1.2 +1.2 glomerular mesangial +1,2 +1.2 .1.2 cells fibroblasts +2 +1.2 +2 aortic sm. muscle +1.2 1= protein expression shown. 2= mRNA expression shown.

However, a distinctly different pattern is seen in several other cell types shown in Table 3 including glomerular mesangial cells, rat aortic smooth muscle and fibroblasts. In these cells, expression of gp91phox is absent while p22phox and in some cases cytosolic phox components have been demonstrated to be present. Since gp9lphox and p22phox stabilize one another in the neutrophil, there has been much speculation that some molecule, possibly related to gp91phox, accounts for ROI generation in glomerular mesangial cells, rat aortic smooth muscle and fibroblasts (Ushio-Fukai et al. (1996) J. Biol. Chem. 271, 23317-23321). Investigation of fibroblasts from a patient with a genetic absence of gp91phox provides proof that the gp91phox subunit is not involved in ROI generation in these cells (Emmendorffer et al. (1993) Eur. J.

Haematol. 51, 223-227). Depletion of p22phox from vascular smooth muscle using an antisense approach indicated that this subunit participates in ROI generation in these cells, despite the absence of detectable gp91phox (Ushio-Fukai et al. (1996) J.

Biol. Chem. 271, 23317-23321). At this time the molecular candidates possibly related to gp91phox and involved in ROI generation in these cells are unknown.

Accordingly, what is needed is the identity of the proteins involved in ROI generation, especially in nonphagocytic tissues and cells. What is also needed are the nucleotide sequences encoding for these proteins, and the primary sequences of the Sproteins themselves. Also needed are vectors designed to include nucleotides encoding for these proteins.. Probes and PCR primers derived from the nucleotide sequence are O needed to detect, localize and measure nucleotide sequences, including mRNA, involved in the synthesis of these proteins. In addition, what is needed is a means to transfect cells with these vectors. What is also needed are expression systems for Sproduction of these molecules. Also needed are antibodies directed against these molecules for a variety of uses including localization, detection, measurement and t passive immunization.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

SUMMARY OF THE INVENTION The present invention solves the problems described above by providing a novel family of nucleotide sequences and proteins encoded by these nucleotide sequences termed mox proteins and duox proteins. In particular the present invention provides compositions comprising the nucleotide sequences SEQ ID NO:, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47, and fragments thereof, which encode for the expression of proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, respectively, and fragments thereof. While not wanting to be bound by the following statement, it is believed that these proteins are involved in ROI production. The present invention also provides vectors containing these nucleotide sequences, cells transfected with these vectors which produce the proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, and fragments thereof, and antibodies to these proteins and fragments thereof. The present invention also provides methods for stimulating cellular proliferation by administering vectors encoded for r 8a production of the proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. The present invention also WO 00/28031 PCT/US99/26592 9 provides methods for stimulating cellular proliferation by administering the proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. The nucleotides and antibodies of the present invention are useful for the detection, localization and measurement of the nucleic acids encoding for the production of the proteins of the present invention, and also for the detection, localization and measurement of the proteins of the present invention. These nucleotides and antibodies can be combined with other reagents in kits for the purposes of detection, localization and measurement.

Most particularly, the present invention involves a method for regulation of cell division or cell proliferation by modifying the activity or expression of the proteins described as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 or fragments thereof. These proteins, in their naturally occurring or expressed forms, are expected to be useful in drug development, for example for screening of chemical and drug libraries by observing inhibition of the activity of these enzymes. Such chemicals and drugs would likely be useful as treatments for cancer, prostatic hypertrophy, benign prostatic hypertrophy, hypertension, atherosclerosis and many other disorders involving abnormal cell growth or proliferation as described below. The entire expressed protein may be useful in these assays. Portions of the molecule which may be targets for inhibition or modification include but are not limited to the binding site for pyridine nucleotides (NADPH or NADH), the flavoprotein domain (approximately the C-terminal 265 amino acids), and/or the binding or catalytic site for flavin adenine dinucleotide (FAD). The method of the present invention may be used for the development of drugs or other therapies for the treatment of conditions associated with abnormal growth including, but not limited to the following: cancer, psoriasis, prostatic hypertrophy, benign prostatic hypertrophy, cardiovascular disease, proliferation of vessels, including but not limited to blood vessels and lymphatic vessels, arteriovenous malformation, vascular problems associated with the eye, atherosclerosis, hypertension, and restenosis following angioplasty. The enzymes of the present invention are excellent targets for the development of drugs and other agents which may modulate the activity of these enzymes. It is to be understood that modulation of activity may result in enhanced, diminished or absence of enzymatic activity. Modulation of the activity of these enzymes may be useful in treatment of conditions associated with abnormal growth.

Drugs which affect the activity of the enzymes represented in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 21, SEQ ID NO: 42, SEQ ID NO: 46, SEQ ID NO: 48, or fragments thereof, may also be combined with other therapeutics in the treatment of specific conditions. For example, these drugs may be combined with angiogenesis inhibitors in the treatment of cancer, with antihypertensives for the treatment of hypertension, and with cholesterol lowering drugs for the treatment of atherosclerosis.

Accordingly, a desire of the present invention is to provide nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

Another desire of the present invention is to provide vectors containing these nucleotide sequences, or fragments thereof.

Yet another desire of the present invention is to provide cells transfected with these vectors.

Still another desire of the present invention is to administer cells transfected with these vectors to animals and humans.

Another desire of the present invention is to provide proteins, or fragments thereof, that are involved in ROI production.

Still another desire of the present invention is to provide antibodies, including monoclonal and polyclonal antibodies, or fragments thereof, raised against proteins, or fragments thereof, that are involved in ROI production.

Another desire of the present invention is to administer genes containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans and also to cells obtained from animals and humans.

Another desire of the present invention is to administer antisense complimentary sequences of genes containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans and also to cells obtained from animals and humans.

Yet another desire of the present invention is to provide a method for stimulating or inhibiting cellular proliferation by administering vectors containing nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans. It is also a desire of the present invention to provide a method for stimulating or inhibiting cellular proliferation by administering vectors containing antisense complimentary sequences of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production, to animals and humans. These methods of stimulating cellular proliferation are useful for a variety of purposes, including but not limited to, developing animal models of tumor formation, stimulating cellular proliferation of blood marrow cells following chemotherapy or radiation, or in cases of anemia.

Still another desire of the present invention is to provide antibodies useful in immunotherapy against cancers expressing the proteins represented in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 or fragments thereof.

Yet another desire of the present invention is to provide nucleotide probes useful for the detection, localization and measurement of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

Another desire of the present invention is to provide antibodies useful for the detection, localization and measurement of nucleotide sequences, or fragments thereof, encoding for the production of proteins, or fragments thereof, that are involved in ROI production.

Another desire of the present invention is to provide kits useful for detection of nucleic acids including the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47, or fragments thereof, that encode for proteins, or fragments thereof, that are involved in ROI production.

Yet another desire of the present invention is to provide kits useful for detection and measurement of nucleic acids including the nucleic acids represented in SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47, or fragments thereof, that encode for proteins, or fragments thereof, that are involved in ROI production.

Still another desire of the present invention is to provide kits useful for the localization of nucleic acids including the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47, or fragments thereof, that encode for proteins, or fragments thereof that are involved in ROI production.

Another desire of the present invention is to provide kits useful for detection of proteins, including the proteins represented in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, or fragments thereof, that are involved in ROI production.

Yet another desire of the present invention is to provide kits useful for detection and measurement of proteins, including the proteins represented in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, or fragments thereof, that are involved in ROI production.

Still another desire of the present invention is to provide kits useful for localization of proteins, including the proteins represented in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, or fragments thereof, that are involved in ROI production.

Yet another desire of the present invention is to provides kits useful for the detection, measurement or localization of nucleic acids, or fragments thereof, encoding for proteins, or fragments thereof, that are involved in ROI production, for use in diagnosis and prognosis of abnormal cellular proliferation related to ROI production.

Another desire of the present invention is to provides kits useful for the detection, measurement or localization of proteins, or fragments thereof, that are involved in ROI production, for use in diagnosis and prognosis of abnormal cellular proliferation related to ROI production.

These and other desires, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended drawings.

BRIEF DESCRIPTION OF THE FIGURES Fig. 1 Comparison of amino acid sequences of the human moxl protein (labeled moxl.human, SEQ ID NO:2), rat moxl protein (labeled moxl.rat, SEQ ID NO:21), human mox2 protein (labeled mox2.human., SEQ ID NO:4) of the present invention to human (gp 91phox/human.pep, SEQ ID NO:12) bovine (gp 91 phox/bovine.pep, SEQ ID NO: 37), and murine (gp 91 phox/mouse.pep, SEQ ID NO:38) proteins. Also included are related plant enzyme proteins cytb 558.arabidopsis.pep (SEQ ID NO:39) and cytb558. rice. pep, 13 This page has been left blank intentionally.

WO 00/28031 PCT/US99/26592 14 (SEQ ID NO:40). Enclosed in boxes are similar amino acid residues.

Fig. 2. Sequence similarities among proteins related to gp91phox including human moxl (SEQ ID NO:2), human mox2 (SEQ ID NO:4), and rat moxl (SEQ ID NO:21).

The dendrogram indicates the degree of similarity among this family of proteins, and also includes the related plant enzymes.

Fig. 3. Cell free assay for mox-1 activity.

Superoxide generation was measured using the chemiluminescent reaction between lucigenin and superoxide in cell lysates from vector control NEF2 and moxl transfected NIH3T3 cells.

Fig. 4. Superoxide generation by human moxl.

Reduction of NBT in moxl transfected and control fibroblasts was measured in the absence (filled bars) or presence (open bars) or superoxide -dismutase.

Fig. 5. Aconitase (filled bars), lactate dehydrogenase (narrow hatching) and fumarase (broad hatching) were determined in lysates of cells transfected with vector alone (NEF2) or with moxl (YA26, YA28 and YA212).

DETAILED DESCRIPTION OF THE INVENTION The present invention solves the problems described above by providing a novel family of nucleotide sequences and proteins, encoded by these nucleotide sequences, termed mox proteins and duox proteins. The term "mox" refers to "mitogenic oxidase" while the term "duox" refers to "dual oxidase". In particular, the present invention provides novel compositions comprising the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID SEQ ID NO:47, and fragments thereof, which encode, respectively, for the expression of proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof.

Both the mox and duox proteins described herein have homology to the gp91phox protein involved in ROI

I

WO 00/28031 PCT/US99/26592 generation, however, the mox and duox proteins comprise a novel and distinct family of proteins. The mox proteins included in the present invention have a molecular weight of approximately 65 kDa as determined by reducing gel electrophoresis and are capable of inducing ROI generation in cells. As described in more detail below, the mox proteins of the present invention also function in the regulation of cell growth, and are therefore implicated in diseases involving abnormal cell growth such as cancer. The present invention describes mox proteins found in human and rat, however, it is likely that the mox family of genes/proteins is widely distributed among multicellular organisms.

The duox proteins described herein are larger than the mox proteins and have three distinct regions: the amino terminal region having homology to peroxidase proteins, the internal region having homology to calmodulin (CAM) proteins and the carboxy-terminal region having homology to mox proteins. Human duoxl is shown in SEQ ID NO:46 and a portion of human duox2 is shown in SEQ ID NO:48.

Nucleotides encoding duoxl and duox2 proteins are also shown in SEQ ID NO: 45 and SEQ ID NO:47, respectively. In addition to the human duox proteins, comparison of the sequence of human duoxl and human duox2 with genomic databases using BLAST searching resulted in the identification of two homologs of duox in C. elegans (Ce-duoxl and Ceduox2). Drosophila also appears to have at least one duox homolog. Thus, the duox family of genes/proteins is widely distributed among multicellular organisms.

Although not wanting to be bound by the following statement, it is believed that duoxl and duox2 have dual enzymatic functions, catalyzing both the generation of superoxide and peroxidative type reactions. The latter class of reactions utilize hydrogen peroxide as a substrate (and in some cases have been proposed to utilize superoxide as a substrate).

Since hydrogen peroxide is generated spontaneously from the dismutation of superoxide, it is believed that the NAD(P)H WO 00/28031 PCT/US99/26592 16 oxidase domain generates the superoxide and/or hydrogen peroxide which can then be used as a substrate for the peroxidase domain. In support of this hypothesis, a model for the duoxl protein in C. elegans has been developed that has an extracellular N-terminal peroxidase domain, a transmembrane region and a NADPH binding site located on the cytosolic face of the plasma membrane. By analogy with the neutrophil NADPH-oxidase which generates extracellular superoxide, human duoxl is predicted to generate superoxide and its byproduct hydrogen peroxide extracellularly where it can be utilized by the peroxidase domain.

While the ROI generated by duoxl and duox2 may function as does moxl in regulation of cell growth, the presence of the peroxidase domain is likely to confer additional biological functions. Depending upon the co-substrate, peroxidases can participate in a variety of reactions including halogenation such as the generation of hypochlorous acid (HOC!) by myeloperoxidase and the iodination of tyrosine to form thyroxin by thyroid peroxidase. Peroxidases have also been documented to participate in the metabolism of polyunsaturated fatty acids, and in the chemical modification of tyrosine in collagen (by sea urchin ovoperoxidase). Although not wanting to be bound by this statement, it is believed that the predicted transmembrane nature of duoxl facilitates its function in the formation or modification of extracellular matrix or basement membrane. Since the extracellular matrix plays an important role in tumor cell growth, invasion and metastasis, it is believed that the duox type enzymes play a pathogenic role in such conditions.

In addition to the nucleotide sequences described above, the present invention also provides vectors containing these nucleotide sequences and fragments thereof, cells transfected with these vectors which produce the proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof, and antibodies to these proteins and fragments thereof.

WO 00/28031 PCT/US99/26592 17 The present invention also provides methods for stimulating cellular proliferation by administering vectors, or cells containing vectors, encoded for production of the proteins comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. The nucleotides and antibodies of the present invention are useful for the detection, localization and measurement of the nucleic acids encoding for the production of the proteins of the present invention, and also for the detection, localization and measurement of the proteins of the present invention. These nucleotides and antibodies can be combined with other reagents in kits for the purposes of detection, localization and measurement. These kits are useful for diagnosis and prognosis of conditions involving cellular proliferation associated with production of reactive oxygen intermediates.

The present invention solves the problems described above by providing a composition comprising the nucleotide sequence SEQ ID NO:1 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:3 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:22 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:41 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:45 and fragments thereof. The present invention also provides a composition comprising the nucleotide sequence SEQ ID NO:47 and fragments thereof.

The present invention provides a composition comprising the protein SEQ ID NO:2 encoded by the nucleotide sequence SEQ ID NO:1. The present invention provides a composition comprising the protein SEQ ID NO:4 encoded by the nucleotide sequence SEQ ID NO:3. The present invention provides a composition comprising the protein SEQ ID NO:21 encoded by the nucleotide sequence SEQ ID NO:22. The present invention provides a composition comprising the protein WO 00/28031 PCT/US99/26592 18 SEQ ID NO:42 encoded by the nucleotide sequence SEQ ID NO:41. The present invention provides a composition comprising the protein SEQ ID NO:46 encoded by the nucleotide sequence SEQ ID NO:45. The present invention provides a composition comprising the protein SEQ ID NO:48 encoded by the nucleotide sequence SEQ ID NO:47.

The present invention provides a composition comprising the protein SEQ ID NO:2 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:1 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:4 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:3 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:21 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:22 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:42 or fragments thereof, encoded by the nucleotide sequence SEQ ID NO:41 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:46 or fragments thereof, encoded by the nucleotide sequence

SEQ

ID NO:45 or fragments thereof. The present invention also provides a composition comprising the protein SEQ ID NO:48 or fragments thereof, encoded by the nucleotide sequence

SEQ

ID NO:47 or fragments thereof.

The present invention also provides vectors containing the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45,

SEQ

ID NO:47 or fragments thereof. The present invention also provides cells transfected with these vectors. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:22 or fragments thereof. The WO 00/28031 PCT/US99/26592 19 present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:41 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:45 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:47 or fragments thereof.

The present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof, which produce the protein SEQ ID NO:2 or fragments thereof. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof which produce the protein SEQ ID NO:4 or fragments thereof. In addition, the present invention provides cells stably transfected with the nucleotide sequence SEQ ID NO:22 or fragments thereof which produce the protein SEQ ID NO:21 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:41 or fragments thereof which produce the protein SEQ ID NO:42 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:45 or fragments thereof which produce the protein SEQ ID NO:46 or fragments thereof. The present invention also provides cells stably transfected with the nucleotide sequence SEQ ID NO:47 or fragments thereof which produce the protein SEQ ID NO:48 or fragments thereof.

The present invention provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:1 which produce the protein SEQ ID NO:2 or fragments thereof. The present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof, which produce the protein SEQ ID NO:4 or fragments thereof. The present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:22 or fragments thereof, which produce WO 00/28031 PCT/US99/26592 the protein SEQ ID NO:21 or fragments thereof. The present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:41 or fragments thereof, which produce the protein SEQ ID NO:42 or fragments thereof. The present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:45 or fragments thereof, which produce the protein SEQ ID NO:46 or fragments thereof. The present invention also provides a method for stimulating growth by administering cells stably transfected with the nucleotide sequence SEQ ID NO:47 or fragments thereof, which produce the protein SEQ ID NO:48 or fragments thereof.

Specifically, the present invention provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:1 or fragments thereof, which produce the protein SEQ ID NO:2 or fragments thereof. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:3 or fragments thereof, which produce the protein SEQ ID NO:4 or fragments thereof. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:22 or fragments thereof, which produce the protein SEQ ID NO:21 or fragments thereof. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:41 or fragments thereof, which produce the protein SEQ ID NO:42 or fragments thereof. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID or fragments thereof, which produce the protein SEQ ID NO:46 or fragments thereof.. The present invention also provides a method for stimulating tumor formation by administering cells stably transfected with the nucleotide sequence SEQ ID NO:47 WO 00/28031 PCTIUS99/26592 21 or fragments thereof, which produce the protein SEQ ID NO:48 or fragments thereof.

The present invention may also be used to develop anti-sense nucleotide sequences to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47 or fragments thereof. These anti-sense molecules may be used to interfere with translation of nucleotide sequences, such as SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47, or fragments thereof, that encode for proteins such as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 or fragments thereof. Administration of these anti-sense molecules, or vectors encoding for anti sense molecules, to humans and animals, would interfere with production of proteins such as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, or fragments thereof, thereby decreasing production of ROIs and inhibiting cellular proliferation. These methods are useful in producing animal models for use in study of tumor development and vascular growth, and for study of the efficacy of treatments for affecting tumor and vascular growth in vivo.

The present invention also provides a method for high throughput screening of drugs and chemicals which modulate the proliferative activity of the enzymes of the present invention, thereby affecting cell division. Combinatorial chemical libraries may be screened for chemicals which modulate the proliferative activity of these enzymes. Drugs and chemicals may be evaluated based on their ability to modulate the enzymatic activity of the expressed or endogenous proteins, including those represented by SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 or fragments thereof. Endogenous proteins may be obtained from many different tissues or cells, such as colon cells. Drugs may also be evaluated based on their ability to bind to the expressed or endogenous proteins represented by SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID WO 00/28031 PCT/US99/26592 22 NO:46, SEQ ID NO:48 or fragments thereof. Enzymatic activity may be NADPH- or NADH-dependent superoxide generation catalyzed by the holoprotein. Enzymatic activity may also be NADPH- or NADH-dependent diaphorase activity catalyzed by either the holoprotein or the flavoprotein domain.

By flavoprotein domain, is meant approximately the C-terminal half of the enzymes shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, or fragments thereof, and the C-terminal end of the enzymes shown in SEQ ID NO:46 and SEQ ID NO:48 (approximately the C-terminal 265 amino acids). This fragment of gp91phox has NADPHdependent reductase activity towards cytochrome c, nitrobluetetrazolium and other dyes. Expressed proteins or fragments thereof can be used for robotic screens of existing combinatorial chemical libraries. While not wanting to be bound by the following statement, it is believed that the NADPH or NADH binding site and the FAD binding site are useful for evaluating the ability of drugs and other compositions to bind to the mox and duox enzymes or to modulate their enzymatic activity. The use of the holoprotein or the C-terminal half or end regions are preferred for developing a high throughput drug screen. Additionally, the N-terminal one-third of the duox domain (the peroxidase domain) may also be used to evaluate the ability of drugs and other compositions to inhibit the peroxidase activity, and for further development of a high throughput drug screen.

The present invention also provides antibodies directed to the proteins SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. The antibodies of the present invention are useful for a variety of purposes including localization, detection and measurement of the proteins SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. The antibodies may be employed in kits to accomplish these purposes. These antibodies may also be linked to cytotoxic agents for selected killing of cells. The WO 00/28031 PCT/US99/26592 23 term antibody is meant to include any class of antibody such as IgG, IgM and other classes. The term antibody also includes a completely intact antibody and also fragments thereof, including but not limited to Fab fragments and Fab Fc fragments.

The present invention also provides the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47 and fragments thereof. These nucleotides are useful for a variety of purposes including localization, detection, and measurement of messenger RNA involved in synthesis of the proteins represented as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. These nucleotides may also be used in the construction of labeled probes for the localization, detection, and measurement of nucleic acids such as messenger RNA or alternatively for the isolation of larger nucleotide sequences containing the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:47 or fragments thereof. These nucleotide sequences may be used to isolate homologous strands from other species using techniques known to one of ordinary skill in the art. These nucleotide sequences may also be used to make probes and complementary strands. In particular, the nucleotide sequence shown in SEQ ID NO:47 may be used to isolate the complete coding sequence for duox2. The nucleotides may be employed in kits to accomplish these purposes.

Most particularly, the present invention involves a method for modulation of growth by modifying the proteins represented as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 or fragments thereof.

The term "mitogenic regulators" is used herein to mean any molecule that acts to affect cell division.

The term "animal" is used herein to mean humans and non-human animals of both sexes.

WO 00/28031 PCT/US99/26592 24 The terms "an" and "the" as used herein are defined to mean one or more and include the plural unless the context is inappropriate.

"Proteins", "peptides," "polypeptides" and "oligopeptides" are chains of amino acids (typically L-amino acids) whose alpha carbons are linked through peptide bonds formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain the carboxy terminal) has a free carboxyl group.

As such, the term "amino terminus" (abbreviated N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an arrmino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids amino acid mimetics). Moreover, an amide bond mimetic includes peptide backbone modifications well known to those skilled in the art.

WO 00/28031 PCT/US99/26592 Furthermore, one of skill will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than more typically less than in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another: 1) Alanine Serine Threonine 2) Aspartic acid Glutamic acid 3) Asparagine Glutamine 4) Arginine Lysine Isoleucine Leucine Methionine Valine and 6) Phenylalanine Tyrosine Tryptophan When the peptides are relatively short in length less than about 50 amino acids), they are often synthesized using standard chemical peptide synthesis techniques. Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is a preferred method for the chemical synthesis of the antigenic epitopes described herein. Techniques for solid phase synthesis are known to those skilled in the art.

Alternatively, the antigenic epitopes described herein are synthesized using recombinant nucleic acid methodology. Generally, this involves creating a nucleic acid sequence that encodes the peptide or protein, placing the nucleic acid in an expression cassette under the control of a particular promoter, expressing the peptide or protein in a host, isolating the expressed peptide or protein and, if required, renaturing the WO 00/28031 PCT/US99/26592 26 peptide or protein. Techniques sufficient to guide one of skill through such procedures are found in the literature.

When several desired protein fragments or peptides are encoded in the nucleotide sequence incorporated into a vector, one of skill in the art will appreciate that the protein fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join the desired protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may be built into the vector. Such sequences are known in the art. For example, a nucleotide sequence encoding for a poly histidine sequence may be added to a vector to facilitate purification of the expressed recombinant protein on a nickel column.

Once expressed, recombinant peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like. Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

One of skill in the art will recognize that after chemical synthesis, biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides.

In this case, it is often necessary to denature and reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and denaturing proteins WO 00/28031 PCT/US99/26592 27 and inducing re-folding are well known to those of skill in the art.

The genetic constructs of the present invention include coding sequences for different proteins, fragments thereof, and peptides. The genetic constructs also include epitopes or domains chosen to permit purification or detection of the expressed protein. Such epitopes or domains include DNA sequences encoding the glutathione binding domain from glutathione S-transferase, hexa-histidine, thioredoxin, hemagglutinin antigen, maltose binding protein, and others commonly known to one of skill in the art. The preferred genetic construct includes the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID SEQ ID NO:47 or fragments thereof. It is to be understood that additional or alternative nucleotide sequences may be included in the genetic constructs in order to encode for the following: a) multiple copies of the desired proteins, fragments thereof, or peptides; b) various combinations of the desired proteins, fragments thereof, or peptides; and c) conservative modifications of the desired proteins, fragments thereof, or peptides, and combinations thereof. Preferred proteins include the human moxl protein and human mox2 protein shown as SEQ ID NO:2 and SEQ ID NO:4, respectively, and fragments thereof. Some preferred fragments of the human moxl protein (SEQ ID NO:2) include but are not limited to the proteins shown as SEQ ID NO:23, SEQ ID NO:24, and SEQ ID The protein moxl is also called p65mox in this application. Another preferred protein of the present invention is rat moxl protein shown as SEQ ID NO:21 and fragments thereof. Another preferred protein of the present invention is rat moxlB protein shown as SEQ ID NO:42 and fragments thereof. Yet another preferred protein of the present invention is duoxl protein shown as SEQ ID NO:46 and fragments thereof. Still another preferred protein of the present invention is duox2 protein. A partial amino acid sequence of the duox2 protein is shown as SEQ ID NO:48.

WO 00/28031 PCT/US99/26592 28 The nucleotide sequences of the present invention may also be employed to hybridize to nucleic acids such as DNA or RNA nucleotide sequences under high stringency conditions which permit detection, for example, of alternately spliced messages.

The genetic construct is expressed in an expression system such as in NIH 3T3 cells using recombinant sequences in a pcDNA-3 vector (Invitrogen, Carlsbad, CA) to produce a recombinant protein. Preferred expression systems include but are not limited to Cos-7 cells, insect cells using recombinant baculovirus, and yeast. It is to be understood that other expression systems known to one of skill in the art may be used for expression of the genetic constructs of the present invention.

The preferred proteins of the present invention are the proteins referred to herein as human moxl and human mox2 or fragments thereof which have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively, or an amino acid sequence having amino acid substitutions as defined in the definitions that do not significantly alter the function of the recombinant protein in an adverse manner. Another preferred protein of the present invention is referred to herein as rat moxl and has the amino acid sequence set forth in SEQ ID NO:21. Yet another preferred protein of the present invention is referred to herein as rat moxlB and has the amino acid sequence set forth in SEQ ID NO:42. Two other preferred proteins of the present invention are referred to herein as human duoxl and human duox2, or fragments thereof, which have the amino acid sequences set forth in SEQ ID NO:46 and SEQ ID NO:48, respectively, or an amino acid sequence having amino acid substitutions as defined in the definitions that do riot significantly alter the function of the recombinant protein in an adverse manner.

Terminology It should be understood that some of the terminology used to describe the novel mox and duox proteins WO 00/28031 PCT/US99/26592 29 contained herein is different from the terminology in U.S.

Provisional Application Serial No. 60/107,911 and U.S.

Provisional Application Serial No. 60/149,332 upon which this application claims priority in part. As described herein, the term "human moxl" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:2, or a fragment thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:1, or a fragment thereof. As described herein, the term "human mox2" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:4, or a fragment thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:3, or a fragment thereof. As described herein, the term "human duoxl" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:46, or a fragment thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:45, or a fragment thereof. As described herein, the term "human duox2" refers to a protein comprising an amino acid sequence as set forth in SEQ ID NO:48, or a fragment thereof, and encoded by the nucleotide sequence as set forth in SEQ ID NO:47, or a fragment thereof.

Construction of the Recombinant Gene The desired gene is ligated into a transfer vector, such as pcDNA3, and the recombinants are used to transform host cells such as Cos-7 cells. It is to be understood that different transfer vectors, host cells, and transfection methods may be employed as commonly known to one of ordinary skill in the art. Six desired genes for use in transfection are shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47. For example, lipofectamine-mediated transfection and in vivo homologous recombination was used to introduce the moxl gene into NIH 3T3 cells.

The synthetic gene is cloned and the recombinant construct containing mox or duox gene is produced and grown in confluent monolayer cultures of a Cos-7 cell line. The WO 00/28031 PCT/US99/26592 expressed recombinant protein is then purified, preferably using affinity chromatography techniques, and its purity and specificity determined by known methods.

A variety of expression systems may be employed for expression of the recombinant protein. Such expression methods include, but are not limited to the following: bacterial expression systems, including those utilizing E. coli and Bacillus subtilis; virus systems; yeast expression systems; cultured insect and mammalian cells; and other expression systems known to one of ordinary skill in the art.

Transfection of Cells It is to be understood that the vectors of the present invention may be transfected into any desired cell or cell line.

Both in vivo and in vitro transfection of cells are contemplated as part of the present invention. Preferred cells for transfection include but are not limited to the following: fibroblasts (possibly to enhance wound healing and skin formation), granulocytes (possible benefit to increase function in a compromised immune system as seen in AIDS, and aplastic anemia), muscle cells, neuroblasts, stem cells, bone marrow cells, osteoblasts, B lymphocytes, and T lymphocytes.

Cells may be transfected with a variety of methods known to one of ordinary skill in the art and include but are not limited to the following: electroporation, gene gun, calcium phosphate, lipofectamine, and fugene, as well as adenoviral transfection systems.

Host cells transfected with the nucleic acids represented in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47, or fragments thereof, are used to express the proteins SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46 and SEQ ID NO:48, respectively, or fragments thereof.

These expressed proteins are used to raise antibodies. These antibodies may be used for a variety of applications including but not limited to immunotherapy against WO 00/28031 PCT/US99/26592 31 cancers expressing one of the mox or duox proteins, and for detection, localization and measurement of the proteins shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46 or SEQ ID NO:48 or fragments thereof.

Purification and Characterization of the Expressed Protein The proteins of the present invention can be expressed as a fusion protein with a poly histidine component, such as a hexa histidine, and purified by binding to a metal affinity column using nickel or cobalt affinity matrices. The protein can also be expressed as a fusion protein with glutathione S-transferase and purified by affinity chromatography using a glutathione agarose matrix. The protein can also be purified by immunoaffinity chromatography by expressing it as a fusion protein, for example with hemagglutinin antigen. The expressed or naturally occurring protein can also be purified by conventional chromatographic and purification methods which include anion and cation exchange chromatography, gel exclusion chromatography, hydroxylapatite chromatography, dye binding chromatography, ammonium sulfate precipitation, precipitation in organic solvents or other techniques commonly known to one of skill in the art.

Methods of Assessing Activity of Expressed Proteins Different methods are available for assessing the activity of the expressed proteins of the present invention, including but not limited to the proteins represented as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46 or SEQ ID NO:48 substituted analogs thereof, and fragments thereof.

1. Assays of the holoprotein and fragments thereof for superoxide generation: A. General considerations.

WO 00/28031 PCT/US99/26592 32 These assays are useful in assessing efficacy of drugs designed to modulate the activity of the enzymes of the present invention. The holoprotein may be expressed in COS-7 cells, NIH 3T3 cells, insect cells (using baculoviral technology) or other cells using methods known to one of skill in the art.

Membrane fractions or purified protein are used for the assay.

The assay may require or be augmented by other cellular proteins such as p47phox, p67phox, and Racl, as well as potentially other unidentified factors kinases or other regulatory proteins).

B. Cytochrome c reduction.

NADPH or NADH is used as the reducing substrate, in a concentration of about 100 gM. Reduction of cytochrome c is monitored spectrophotometrically by the increase in absorbance at 550 nm, assuming an extinction coefficient of 21 mM- cm-1. The assay is performed in the absence and presence of about 10 jtg superoxide dismutase. The superoxidedependent reduction is defined as cytochrome c reduction in the absence of superoxide dismutase minus that in the presence of superoxide dismutase (Uhlinger et al. (1991) J. Biol. Chem.

266, 20990-20997). Acetylated cytochrome c may also be used, since the reduction of acetylated cytochrome c is thought to be exclusively via superoxide.

C. Nitroblue tetrazolium reduction.

For nitroblue tetrazolium (NBT) reduction, the same general protocol is used, except that NBT is used in place of cytochrome c. In general, about 1 mL of filtered 0.25 nitrotetrazolium blue (Sigma, St. Louis, MO) is added in Hanks buffer without or with about 600 Units of superoxide dismutase (Sigma) and samples are incubated at approximately 37°C. The oxidized NBT is clear, while the reduced NBT is blue and insoluble. The insoluble product is collected by centrifugation, and the pellet is re-suspended in about 1 mL of pyridine (Sigma) and heated for about 10 minutes at 100 0 C to solubilize IWO 00/28031 PCT/US99/26592 33 the reduced NBT. The concentration of reduced NBT is determined by measuring the absorbance at 510 nm, using an extinction coefficient of 11,000 M- cm- 1 Untreated wells are used to determine cell number.

D. Luminescence.

Superoxide generation may also be monitored with a chemiluminescence detection system utilizing lucigenin (bis-Nmethylacridinium nitrate, Sigma, St. Louis, MO). The sample is mixed with about 100 gM NADPH (Sigma, St. Louis, MO) and 10 jiM lucigenin (Sigma, St. Louis, MO) in a volume of about 150 gpL Hanks solution. Luminescence is monitored in a 96-well plate using a LumiCounter (Packard, Downers Grove, IL) for 0.5 second per reading at approximately 1 minute intervals for a total of about 5 minutes; the highest stable value in each data set is used for comparisons. As above, superoxide dismutase is added to some samples to prove that the luminescence arises from superoxide. A buffer blank is subtracted from each reading (Ushio-Fukai et al. (1996) J. Biol.

Chem. 271, 23317-23321).

E. Assays in intact cells.

Assays for superoxide generation may be performed using intact cells, for example, the mox-transfected NIH 3T3 cells. In principle, any of the above assays can be used to evaluate superoxide generation using intact cells, for example, the mox-transfected NIH 3T3 cells. NBT reduction is a preferred assay method.

2. Assays of truncated proteins comprised of approximately the C-terminal 265 amino acid residues While not wanting to be bound by the following statement, the truncated protein comprised of approximately the C-terminal 265 amino acid residues is not expected to generate superoxide, and therefore, superoxide dismutase is not added in assays of the truncated protein. Basically, a similar assay is WO 00/28031 PCT/US99/26592 34 established and the superoxide-independent reduction, of NBT, cytochrome c, dichlorophenolindophenol, ferricyanide, or another redox-active dye is examined.

Nucleotides and Nucleic Acid Probes The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47, as well as fragments thereof and PCR primers therefor, may be used, respectively, for localization, detection and measurement of nucleic acids related to SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47, as well as fragments thereof. The nucleotide sequences SEQ ID NO:1 and SEQ ID NO:3 are also called the human moxl gene and the human mox2 gene in this application.

SEQ ID NO:22 is also known as the rat moxl gene in this application. SEQ ID NO:41 is also known as the rat moxlB gene in this application. SEQ ID NO:45 is also known as the human duoxl gene in this application. SEQ ID NO:47 is also known as the human duox2 gene in this application.

The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47, as well as fragments thereof, may be used to create probes to isolate larger nucleotide sequences containing the nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47, respectively. The nucleotide sequences SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47, as well as fragments thereof, may also be used to create probes to identify and isolate mox and duox proteins in other species.

The nucleic acids described herein include messenger RNA coding for production of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. Such nucleic acids include but are not limited to cDNA probes. These probes may be labeled in a variety of ways known to one of ordinary skill in WO 00/28031 PCT/US99/26592 the art. Such methods include but are not limited to isotopic and non-isotopic labeling. These probes may be used for in situ hybridization for localization of nucleic acids such as mRNA encoding for SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. Localization may be performed using in situ hybridization at both ultrastructural and light microscopic levels of resolution using techniques known to one of ordinary skill in the art.

These probes may also be employed to detect and quantitate nucleic acids and mRNA levels using techniques known to one of ordinary skill in the art including but not limited to solution hybridization.

Antibody Production The proteins shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48, or fragments thereof, are combined with a pharmaceutically acceptable carrier or vehicle to produce a pharmaceutical composition and administered to animals for the production of polyclonal antibodies using methods known to one of ordinary skill in the art. The preferred animals for antibody production are rabbits and mice. Other animals may be employed for immunization with these proteins or fragments thereof. Such animals include, but are not limited to the following; sheep, horses, pigs, donkeys, cows, monkeys and rodents such as guinea pigs and rats.

The terms "pharmaceutically acceptable carrier or pharmaceutically acceptable vehicle" are used herein to mean any liquid including but not limited to water or saline, oil, gel, salve, solvent, diluent, fluid ointment base, liposome, micelle, giant micelle, and the like, which is suitable for use in contact with living animal or human tissue without causing adverse physiological responses, and which does not interact with the other components of the composition in a deleterious manner.

WO 00/28031 PCTIUS99/26592 36 The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers.

Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use.

Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets commonly used by one of ordinary skill in the art.

Preferred unit dosage formulations are those containing a dose or unit, or an appropriate fraction thereof, of the administered ingredient. It should be understood that in addition to the ingredients, particularly mentioned above, the formulations of the present invention may include other agents commonly used by one of ordinary skill in the art.

The pharmaceutical composition may be administered through different routes, such as oral, including buccal and sublingual, rectal, parenteral, aerosol, nasal, intramuscular, subcutaneous, intradermal, and topical. The pharmaceutical composition of the present invention may be administered in different forms, including but not limited to solutions, emulsions and suspensions, microspheres, particles, microparticles, nanoparticles, and liposomes. It is expected that WO 00/28031 PCT/US99/26592 37 from about 1 to 7 dosages may be required per immunization regimen. Initial injections may range from about 0.1 jtg to 1 mg, with a preferred range of about 1 Ig to 800 jig, and a more preferred range of from approximately 25 tg to 500 gtg.

Booster injections may range from 0.1 tg to 1-mg, with a preferred range of approximately 1 Ig to 800 gg, and a more preferred range of about 10 gg to 500 jgg.

The volume of administration will vary depending on the route of administration and the size of the recipient. For example, intramuscular injections may range from about 0.1 ml to 1.0 ml.

The pharmaceutical composition may be stored at temperatures of from about 4 0 C to -100 0 C. The pharmaceutical composition may also be stored in a lyophilized state at different temperatures including room temperature. The pharmaceutical composition may be sterilized through conventional means known to one of ordinary skill in the art. Such means include, but are not limited to filtration, radiation and heat. The pharmaceutical composition of the present invention may also be combined with bacteriostatic agents, such as thimerosal, to inhibit bacterial growth.

Adjuvants A variety of adjuvants known to one of ordinary skill in the art may be administered in conjunction with the protein in the pharmaceutical composition. Such adjuvants include, but are not limited to the following: polymers, copolymers such as polyoxyethylene-polyoxypropylene copolymers, including block co-polymers; polymer P1005; Freund's complete adjuvant (for animals); Freund's incompleteadjuvant; sorbitan monooleate; squalene; CRL-8300 adjuvant; alum; QS 21, muramyl dipeptide; trehalose; bacterial extracts, including mycobacterial extracts; detoxified endotoxins; membrane lipids; or combinations thereof.

Monoclonal antibodies can be produced using hybridoma technology in accordance with methods well known WO 00/28031 PCT/US99/26592 38 to those skilled in the art. The antibodies are useful as research or diagnostic reagents or can be used for passive immunization.

The composition may optionally contain an adjuvant.

The polyclonal and monoclonal antibodies useful as research or diagnostic reagents may be employed for detection and measurement of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 and fragments thereof. Such antibodies may be used to detect these proteins in a biological sample, including but not limited to samples such as cells, cellular extracts, tissues, tissue extracts, biopsies, tumors, and biological fluids. Such detection capability is useful for detection of disease related to these proteins to facilitate diagnosis and prognosis and to suggest possible treatment alternatives.

Detection may be achieved through the use of immunocytochemistry, ELISA, radioimmunoassay or other assays as commonly known to one of ordinary skill in the art.

The moxl, mox2, duoxl and duox2 proteins, or fragments thereof, may be labeled through commonly known approaches, including but not limited to the following: radiolabeling, dyes, magnetic particles, biotin-avidin, fluorescent molecules, chemiluminescent molecules and systems, ferritin, colloidal gold, and other methods known to one of skill in the art of labeling proteins.

Administration of Antibodies The antibodies directed to the proteins shown as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46 or SEQ ID NO:48, or directed to fragments thereof, may also be administered directly to humans and animals in a passive immunization paradigm. Antibodies directed to extracellular portions of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46 or SEQ ID NO:48 bind to these extracellular epitopes. Attachment of labels to these antibodies facilitates localization and visualization of sites of binding. Attachment of molecules such as ricin or WO 00/28031 PCT/US99/26592 39 other cytotoxins to these antibodies helps to selectively damage or kill cells expressing SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:48 or fragments thereof.

Kits The present invention includes kits useful with the antibodies, nucleic acids, nucleic acid probes, labeled antibodies, labeled proteins or fragments thereof for detection, localization and measurement of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48 or combinations and fragments thereof.

Kits may be used for immunocytochemistry, in situ hybridization, solution hybridization, radioimmunoassay, ELISA, Western blots, quantitative PCR, and other assays for the detection, localization and measurement of these nucleic acids, proteins or fragments thereof using techniques known to one of skill in the art.

The nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID SEQ ID NO:47, or fragments thereof, may also be used under high stringency conditions to detect alternately spliced messages related to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45, SEQ ID NO:47 or fragments thereof, respectively.

As discussed in one of the Examples, rat moxl protein (SEQ ID NO: 21) is similar to mouse gp91 protein (SEQ ID NO: 38), whereas rat moxlB protein (SEQ ID NO:42) is similar to human gp91 protein (SEQ ID NO:12). This observation suggests that other isoforms of mouse and human gp91 may exist. In addition, another subtype of human moxl, similar to rat moxlB (SEQ ID NO:42), also exists. The presence of two isoforms of rat moxl protein in vascular smooth muscle may have important physiological consequences WO 00/28031 PCT/US99/26592 and biomedical applications. For example, the two isoforms may have different biological activities, different tissue distributions and may be regulated differently in physiological and/or pathological conditions. The fact that moxlB (SEQ ID NO:42) was isolated from cells exposed to angiotensin

II,

known to promote oxidative stress and vascular growth, suggests that it may be upregulated by this hormone and may be overexpressed in disease. Therefore, the diagnostic kits of the present invention can measure the relative expression of the two mox isoforms. The diagnostic kits may also measure or detect the relative expression of the mox proteins described herein human moxl and/or human mox2) and duox proteins described herein human duoxl and/or human duox2).

Fragments of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41 SEQ ID NO:45 and SEQ ID NO:47 containing the relevant hybridizing sequence can be synthesized onto the surface of a chip array. RNA samples, from tumors, are then fluorescently tagged and hybridized onto the chip for detection. This approach may be used diagnostically to characterize tumor types and to tailor treatments and/or provide prognostic information. Such prognostic information may have predictive value concerning disease progression and life span, and may also affect choice of therapy.

The present invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention.

WO 00/28031 PCT/US99/26592 41 EXAMPLE 1 Sequence Analysis and Cloning of the Human mox] cDNA (SEQ ID NO:1) Encoding for Production of the Human moxl Protein p65mox (SEQ ID NO:2) Using gp91phox as a query sequence, a 334 base sequenced portion of expressed sequence tag (EST) 176696 (GenBank Accession number AA305700) showed 68.8% sequence identity at the predicted amino acid level with human gp91phox. The bacterial strain number 129134 containing the EST sequence in the pBluescript SK- vector, was purchased from American Tissue Type Culture Collection

(ATCC,

Rockville, MD). The EST sequence was originally cloned from a Caco-2 human colon carcinoma cell line. The EST176696 DNA was further sequenced using the T7 and T3 vector promoters and primers designed to match the known 3' sequence. Internal primers used for sequencing were as follows: 5'-AAC AAG CGT GGC TIC AGC ATG-3' SEQ ID (251S, numbering is based on the nucleotides from the end of EST176696, and S indicates the sense direction), AAT ATT GTT GGT CAT-3' SEQ ID NO:6 (336S), TTG ACA GAA AAT CTA TAA GGG-3' SEQ ID NO:7 (393S), 5'-TTG TAC CAG ATG GAT TTC AA-3' SEQ ID NO:8 (673A, A indicates the antisense direction), 5'-CAG GTC TGA AAC AGA AAA CCT-3' SEQ ID NO:9 (829S), AAT TCT CAT TAA TTA TTC AAT AAA-3' SEQ ID (1455A). The coding sequence in EST176696 showed homology to a 250 amino acid stretch corresponding to the Nterminal 44% of human gp91phox, and contained a stop codon corresponding to the location in human gp91phox. 5' Rapid amplification of cDNA ends (RACE) was carried out using ahuman colon cDNA library and Marathon cDNA Amplification Kit (ClonTech) using 5'-ATC TCA AAA GAC TCT GCA CA- 3' SEQ ID NO:11 (41A) as an internal gene-specific primer (Frohman et al. (1988) Proc. Natl. Acad. Sci. USA 85, 8998- 9002). 5' RACE resulted in a 1.1 kb fragment representing the complete 5' sequence, based on homology with gp9lphox.

WO 00/28031 PCT/US99/26592 42 Reamplification was performed with primers spanning the putative start and stop codons, using the 1.1 kb 5' RACE product and pSK-EST176696 for primer design. The amplified 1.7kb fragment was TA cloned into the PCR2.1 vector (Invitrogen, Carlsbad, CA). This recombinant vector is referred to as PCR-mox.

Figure 1(a-d) presents a comparison of the present amino acid sequences of human, bovine and murine gp91 phox with the human and rat mox1 proteins of the present invention and the human duox2 protein of the present invention. Also shown are the amino acid sequences for related plant enzyme proteins.

The encoded hp65mox ("mox" referring to mitogenic oxidase and "65" referring to its predicted molecular weight) is listed as SEQ ID NO:2. h-gp91phox (SEQ ID NO: 12) and SEQ ID NO:2 differ in length by 3 residues and are identical in their amino acid sequence. h-gp91phox and SEQ ID NO:2 show a greater percentage identity in the Cterminal half of the molecule which contains the putative NADPH and FAD binding sites, and there are several relatively long stretches of complete identity within this region.

A dendrogram (Figure 2) comparing the amino acid sequences of mouse and human gp91phox with that of moxl SEQ ID NO:2 shows that the latter probably represents a distinct isoform of gp91phox. Two plant homologs of cytochrome b 5 ss large subunit are also indicated and represent more distant relatives of the human sequences. Human (and rat moxl described more fully below) lack asparagine-linked glycosylation sites, which are seen in the highly glycosylated human and mouse gp91phox. Additionally, the hydropathy profiles of human gp91phox and moxl are nearly identical and include five very hydrophobic stretches in the amino-terminal half of the molecules which are predicted to be membranespanning regions.

WO 00/28031 PCT/US99/26592 43 EXAMPLE 2 Expression of Moxl Human multiple tissue northern (MTN) Blot I and Human MTN Blot IV (ClonTech) membranes were hybridized with the putative coding region of the PCR-mox vector at 68°C for several hours. The mox coding region was labeled by random priming with [a- 32 P]dCTP (10 gCi) using the Prime-It II kit (Stratagene). For analysis of moxl expression in cell lines, total RNA was prepared from 10 6 cells using the High Pure RNA Isolation Kit (Boehringer Mannheim) or RNeasy kit (Quiagen). Total RNA (10-20 gg) was separated on a 1% agarose formaldehyde mini-gel and transferred to a Nytran filter (Biorad) and immobilized by ultraviolet cross-linking.

Northern blotting revealed that the major location of mRNA coding for the moxl protein was colon. The message was also detected in prostate and uterus. The human coloncarcinoma cell line, Caco-2, also expressed large quantities of moxl message. Northern blotting of mRNA from rat aortic smooth muscle cells also showed strong hybridization, which increased roughly two-fold within 12 hours after treatment with platelet-derived growth factor. This increase in the expression of rat moxl is consistent with the idea that moxl contributes to the growth-stimulatory effects of PDGF.

EXAMPLE 3 Transfection of NIH3T3 Cells with SEQ ID NO:] The nucleotide sequence (SEQ ID NO:1) encoding for production of the moxl protein (SEQ ID NO:2) was subcloned into the Notl site of the pEF-PAC vector (obtained from Mary Dinauer, Indiana University Medical School,' Indianapolis, IN) which has a puromycin resistance gene.

Transfection was carried out as described in Sambrook et al., Molecular Cloning, A Laboratory Manual, Volumes 1-3, 2nd edition, Cold Spring Harbor Laboratory Press, 1989.

The SEQ ID NO:1 in pEF-PAC and the empty vector were separately transfected into NIH 3T3 cells using Fugene 6 WO 00/28031 PCT/US99/26592 44 (Boeringer Mannheim). About 2 x 106 cells maintained in DMEM containing 10% calf serum were transfected with 10 upg of DNA. After 2 days, cells were split and selected in the same medium containing Img/ml puromycin. Colonies that survived in selection media for 10 to 14 days were subcultured continuously in the presence of puromycin.

Transfected cells exhibited a "transformed"-like morphology, similar to that seen with (V1 2 )Ras-transfected cells, characterized by long spindle-like cells. The parent NIH 3T3 cells or cells transfected with the empty vector showed a normal fibroblast-like morphology.

EXAMPLE 4 Expression of Moxl (SEQ ID NO:1) in Transfected NIH3T3 Cells To verify the expression of moxl mRNA after transfection, RT-PCR and Northern blotting were performed.

Total RNAs were prepared from 106 cells using the High Pure RNA Isolation Kit (Boeringer Mannheim) or RNeasy kit (Qiagen). cDNAs for each colony were prepared from 1-2 .g of total RNA using Advantage RT-PCR Kit (ClonTech).

PCR

amplification was performed using primers, 5'-TTG GCT AAA TCC CAT CCA-3' SEQ ID NO:13 (NN459S, numbering containing NN indicates numbering from the start codon of moxl) and 5'-TGC ATG ACC AAC AAT ATT GCT G-3' SEQ ID NO:14 (NN1435A). For Northern blotting, 10-20 pg of total RNA was separated on a 1% agarose formaldehyde gel and transferred to a nylon filter. After ultraviolet (UV) crosslinking, filters were used for Northern blotting assay as described in Example 2.

Colonies expressing large amounts of moxl mRNA were chosen for further analysis. The expression of mRNA for glyceraldehyde 3 phosphate dehydrogenase in the various cell lines was normal.

EXAMPLE WO 00/28031 PCT/US99/26592 Colony Formation on Soft Agar 105 to 10 3 cells stably transfected with human moxl gene SEQ ID NO: 1 and with empty vector were prepared in 0.3% warm (40 0 C) agar solution containing DMEM and calf serum. Cells were distributed onto a hardened 0.6% agar plate prepared with DMEM and 10% calf serum. After three weeks in culture (370C, 5% CO2) colony formation was observed by microscopy.

Cells which were stably transfected with the empty vector and cultured in soft agar for 3 weeks as above did not display anchorage independent growth. In contrast, NIH 3T3 cells which had been stably transfected with the mox1 (SEQ ID NO:1) and cultured for 3 weeks in soft agar demonstrated anchorage independent growth of colonies.

EXAMPLE 6 NADPH-Dependent Superoxide Generation Assay In one embodiment of the present invention, NIH 3T3 cells stably transfected with the human moxl gene (SEQ ID NO:1) were analyzed for superoxide generation using the lucigenin (Bis-N-methylacridinium luminescence assay (Sigma, St. Louis, MO, Li et al. (1998) J. Biol. Chem. 273, 2015- 2023). Cells were washed with cold HANKS' solution and homogenized on ice in HANKS' buffer containing 15% sucrose using a Dounce homogenizer. Cell lysates were frozen immediately in a dry ice/ethanol bath. For the assay, 30 jtg of cell lysate was mixed with 200 jLM NADPH and 500 pjM lucigenin. Luminescence was monitored using a LumiCounter (Packard) at three successive one minute intervals and the highest value was used for comparison. Protein concentratiofi was determined by the Bradford method.

Superoxide generation was monitored in lysates from some of the stably transfected cell lines and was compared with superoxide generation by the untransfected NIH 3T3 cell lysates. The results are shown in Table 4. Cell lines 26, 27, and 28 gave the highest degree of morphological changes by WO 00/28031 PCT/US99/26592 46 microscopic examination corresponding to the highest degree of superoxide generation. The luminescent signal was inhibited by superoxide dismutase and the general flavoprotein inhibitor diphenylene iodonium, but was unaffected by added recombinant human p47phox, p67phox and Racl(GTP-yS), which are essential cytosolic factors for the phagocyte respiratory-burst oxidase.

Table 4 Cell Line Name Superoxide Generation

(RLU)

Control (untransfected) 6045 mox1-26 17027 moxl-27 14670 moxl-28 18411 mox1-65 5431 moxl-615 11331 moxl-+3 8645 5425 moxl-pccl6 8050 In an alternate and preferred embodiment of the present invention, cells that had been stably transfected with moxl (YA28) or with empty vector (NEF2) were grown in 10 cm tissue culture plates in medium containing DMEM, 10% calf serum, 100 units/ml penicillin, 100 gpg/ml streptomycin, and 1 tg/ml puromycin to approximately 80% confluency. Cells (five tissue culture plates of each cell type) were washed briefly with ml phosphate buffered saline (PBS) then dissociated from the plates with PBS containing 5 mM EDTA. Cells were pelleted by centrifuging briefly at 1000 x g.

To permeabilize the cells, freeze thaw lysis was carried out and this was followed by passage of the cell material through a small bore needle. The supernatant was removed and the cells were frozen on dry ice for 15 minutes. After cells were thawed, 200 gLl lysis buffer (HANKS' Buffered Salt WO 00/28031 PCT/US99/26592 47 Solution HBBS) containing a mixture of protease inhibitors from Sigma (Catalog P2714) was added. Cells on ice were passed through an 18 guage needle 10 times and 200 4l of HBSS buffer containing 34% sucrose was added to yield a final concentration of 17% sucrose. Sucrose appeared to enhance stability upon storage. The combination of freeze-thawing and passage through a needle results in lysis of essentially all of the cells, and this material is referred to as the "cell lysate." The cell lysates were assayed for protein concentration using the BioRad protein assay system. Cell lysates were assayed for NADPH-dependent chemiluminescence by combining HBSS buffer, arachidonic acid, and 0.01 1 p.g protein in assay plates (96 well plastic plates). The reaction was initiated by adding 1.5 mM NADPH and 75 4M lucigenin to the assay mix to give a final concentration of 200 piM NADPH and tM lucigenin, and the chemiluminescence was monitored immediately. The final assay volume as 150 gl. The optimal arachidonic acid concentration was between 50-100 iM. A Packard Lumicount luminometer was used to measure chemiluminescence of the reaction between lucigenin and superoxide at 37*C. The plate was monitored continuously for minutes and the maximal relative luminescence unit (RLU) value for each sample was used for the graph.

Figure 3 shows the RLU at various concentrations of cell lysates from moxl-transfected (YA28) and vector control (NEF2) cells. The presence of NaCI or KCI within a concentration range of 50-150 jiM is important for optimal activity. MgCl 2 (1-5 mM) further enhanced activity by about 2fold. This cell-free assay for moxl NADPH-oxidase activity is useful for screening modulators (inhibitors or stimulators) of the moxl enzyme. The assay may also be used to detect mox and duox NADPH-oxidase activity in general and to screen for modulators (inhibitors or stimulators) of the mox and duox family of enzymes.

WO 00/28031 PCT/US99/26592 48 EXAMPLE 7 Nitro Blue Tetrazolium Reduction by Superoxide Generated by NIH 3T3 cells Transfected with the Moxl cDNA (SEQ ID NO:1) Superoxide generation by intact cells was monitored by using superoxide dismutase-sensitive reduction of nitroblue tetrazolium. NEF2 (vector alone control), YA26 (moxl (SEQ ID NO:l)-transfected) and YA28 (moxl (SEQ ID NO:l)-transfected) cells were plated in six well plates at 500,000 cells per well. About 24 hours later, medium was removed from cells and the cells were washed once with 1 mL Hanks solution (Sigma, St. Louis, MO). About 1 mL of filtered 0.25% Nitro blue tetrazolium (NBT, Sigma) was added in Hanks without or with 600 units of superoxide dismutase (Sigma) and cells were incubated at 37 0 C in the presence of

CO

2 After 8 minutes the cells were scraped and pelleted at more than 10,000g. The pellet was re-suspended in 1 mL of pyridine (Sigma) and heated for 10 minutes at 100 0 C to solubilize the reduced NBT. The concentration of reduced NBT was determined by measuring the absorbance at 510 nm, using an extinction coefficient of 11,000 M-1cm- 1 Some wells were untreated and used to determine cell number.

The data are presented in Table 5 and Figure 4 and indicate that the moxl (SEQ ID NO:l)-transfected cells generated significant quantities of superoxide.

Table NBT Reduction (nmols/10 6 cells) SOD

SOD

vector control cells 2.5 0.5 2.1 YA26 (mox1) cells 6.4 0.2 3.4 0.1 YA28 (moxl) cells 5.2 0.6 3.4 0.3 -SOD, and +SOD mean in the absence or presence of added superoxide dismutase, respectively.

Because superoxide dismutase is not likely to penetrate cells, superoxide must be generated extracellularly. The amount of WO 00/28031 PCT/US99/26592 49 superoxide generated by these cells is about 5-10% of that generated by activated human neutrophils.

EXAMPLE 8 Modification of Intracellular Components in Moxl Transfected Cells To test whether superoxide generated by moxl can affect intracellular "targets," aconitase activity in control and moxtransfected cell lines was monitored as described in Suh et al.

(1999) Nature 401, 79-82. Aconitase contains a four-ironsulphur cluster that is highly susceptible to modification by superoxide, resulting in a loss of activity, and has been used as a reporter of intra-cellular superoxide generation Acotinase activity was determined as described in Gardner et al. (1995) J.

Biol. Chem. 270, 13399-13405. Acotinase activity was significantly diminished in all three mox-transfected cell lines designated YA26, YA28 and YA212 as compared to the transfected control (Figure Approximately 50% of the aconitase in these cells is mitochondrial, based on differential centrifugation, and the cytosolic and mitochondrial forms were both affected. Control cytosolic and mitochondrial enzymes that do not contain iron-sulfur centres were not affected.

Superoxide generated in moxl-transfected cells is therefore capable of reacting with and modifying intracellular components.

EXAMPLE 9 Tumor Generation in Nude Mice Receiving Cells Transfected with the Human moxl cDNA (SEQ ID NO:1) About 2 x 106 NIH 3T3 cells (either moxltransfected with SEQ ID NO: 1 or cells transfected using empty vector) were injected subdermally into the lateral aspect of the neck of 4-5 week old nude mice. Three to six mice were injected for each of three moxl-transfected cell lines, and 3 mice were injected with the cells transfected with empty vector (control). After 2 to 3 weeks, mice were sacrificed. The tumors were fixed in 10% formalin and characterized by r WO 00/28031 PCT/US99/26592 histological analysis. Tumors averaged 1.5 x 1 x 1 cm in size and showed histology typical of sarcoma type tumors. In addition, tumors appeared to be highly vascularized with superficial capillaries. Eleven of twelve mice injected with moxl gene-transfected cells developed tumors, while none of the three control animals developed tumors.

In another study, 15 mice were injected with moxltransfected NIH 3T3 cells. Of the 15 mice injected, 14 showed large tumors within 17 days of injection, and tumors showed expression of moxl mRNA. Histologically, the tumors resembled fibrosarcomas and were similar to ras-induced tumors. Thus, ras and moxl were similarly potent in their ability to induce tumorigenicity of NIH 3T3 cells in athymic mice.

EXAMPLE Demonstration of the Role of Moxl in Non-Cancerous Growth A role in normal growth was demonstrated in rat aortic vascular smooth-muscle cells by using antisense to rat moxl. Transfection with the antisense DNA resulted in a decrease in both superoxide generation and serum-dependent growth. Moxl is therefore implicated in normal growth in this cell type.

EXAMPLE 11 Expression of Human Moxl Protein (SEQ ID NO:2) in a Baculovirus Expression System SEQ ID NO:2 was also expressed in insect cells using recombinant baculovirus. To establish the expressing virus system, the moxl gene (SEQ ID NO:1) wts initially cloned into the pBacPAK8 vector (Clontech, Palo Alto, CA) and recombinant baculovirus was constructed using standard methods according to manufacturer's protocols.

Briefly, PCR amplified moxl DNA was cloned into the KpnI and EcoRI site of the vector. Primers used for PCR amplification were: 5'-CAA GGT ACC TCT TGA CCA TGG WO 00/28031 PCT/US99/26592 51 GAA ACT-3' SEQ ID NO:15, and 5'-ACG AAT TCA AGT AAA TTA CTG AAG ATA C-3' SEQ ID NO:16. Sf9 insect cells (2 x 106 cells) were infected with 0.5 mg of linearized baculovirus DNA sold under the trademark BACULOGOLD@ (PharMingen, San Diego, CA) and 5 mg pBacPAC8-p65moxl using Transfection Buffers A and B (PharMingen, San Diego, CA). After 5 days, the supernatants containing recombinant viruses were harvested and amplified by infecting fresh sf9 cells for 7 days. Amplification was carried out three times and the presence of the recombinant virus containing moxl DNA was confirmed by PCR using the same primers. After three times amplification of viruses, plaque purification was carried out to obtain the high titer viruses. Approximately 2 x 108 sf9 cells in agar plates were infected for 5 days with serial dilutions of virus and were dyed with neutral red for easy detection of virus plaques. Selected virus plaques were extracted and the presence of the human mox DNA was confirmed again by PCR.

EXAMPLE 12 Cloning of a Rat Homolog of p65mox (SEQ ID NO:2) cDNA clones of p65mox from a rat aortic smooth muscle cell have been obtained. RT-PCR (reverse transcription polymerase chain reaction) was carried out as follows: first strand cDNA synthesis was performed using total RNA from rat aortic vascular smooth muscle cells, oligo dT primer and superscript II reverse transcriptase, and followed by incubation with RNase H. Degenerate PCR primers were designed to anneal to conserved areas in the coding regions of h-moxl and gp91phox of human (X04011), mouse (U43384) and porcine (SSU02476) origin. Primers were: sense CCIGTITGTCGIAATCTGCTSTCCTT-3', SEQ ID NO:17 and antisense 5'-TCCCIGCAIAICCAGTAGAARTAGATCTT-3', SEQ ID NO:18. A major PCR product of the expected 1.1 kb size was purified by agarose electrophoresis and used as template in a second PCR amplification reaction.

An aliquot of the RT-PCR product was blunt- WO 00/28031 PCT/US99/26592 52 ended, ligated into a modified Litmus 29 vector and used to transform XL10 competent E. coli. Approximately 120 bacterial colonies were screened for the presence of a fulllength insert by direct PCR using vector primers and Taq polymerase. Plasmids were purified from 25 positive colonies and mapped by digestion with Bam HI. Representative plasmids from each digestion pattern were partially sequenced. Five out of 25 clones contained non-specific amplification products and contained identical inserts similar to human (h)-moxl. One of the latter clones was fully sequenced and found to be 83% identical to h-moxl over 1060 nucleotides. A 1.1 kb probe was generated by PCR amplification of the insert of a rat moxl clone with the degenerate primers described above and used to hybridize to a Northern blot of rat vascular smooth muscle cell RNA. A single band, migrating between 28S rRNA and 18S rRNA, indicated the presence of a message with a size compatible to that of human mox-1 (2.6 kb).

To obtain full-length rat moxl, 3' and 5' rapid amplification of cDNA ends (RACE) reactions were performed as describe above, using the gene-specific primers TTGGCACAGTCAGTGAGGATGTCTTC-3', SEQ ID NO:19 and 5'-CTGTTGGCTTCTACTGTAGCGTTCAAAGTT-3', SEQ ID NO:20 for 3' and 5' RACE, respectively. Single major kb and 850 bp products were obtained for 3' and 5' RACE, respectively. These products were purified by agarose gel eletrophoresis and reamplified with Taq polymerase. Both products were cloned into the pCR 2.1 vector and used to transform electrocompetent XL1 blue E. coli. The RACE products were sequenced and new terminal primers were designed: sense TTCTGAGTAGGTGTGCATTTGAGTGTCATAAAGAC-3' (SEQ ID NO:43), and antisense

TTTTCCGTCAAAATTATAACTTTTTATTTTCTTTTTATA

ACACAT-3' (SEQ ID NO:44). PCR amplification of rat VSMC cDNA was performed using these primers.

WO 00/28031 PCT/US99/26592 53 A single 2.6 kb product was obtained, ligated into pCR 2.1 and used to transform electrocompetent XL1 blue E.

coli. The insert was sequenced with 12 sense and 14 antisense primers. Its length is 2577 bp (including primer sequences), comprising a 1692 bp open reading frame, 127 bp 5' and 758 bp 3' untranslated regions. The presence of six in-frame stop codons in the 5' untranslated region suggests that the full length coding region has been obtained. Consensus polyadenylation sequences are present at nucleotides 2201 and 2550. Conceptual translation yields a 563 amino acid peptide, one residue shorter than the human deduced sequence. This new amino acid sequence is more similar to human moxl SEQ ID NO:3 (82% identity) than to mouse gp91phox SEQ ID NO:38 identity), suggesting that it is indeed rat moxl (SEQ ID NO:21).

This rat homolog of p65mox protein is called r-p65mox or and is shown as SEQ ID NO:21. The nucleotide sequence encoding for r-p65mox is shown as SEQ ID NO:22.

EXAMPLE 13 Expression of rat (r)-p65mox mRNA in Vascular Smooth Muscle and Induction by Angiotensin II, Platelet-Derived Growth Factor (PDGF), and Phorbol Myristic Acid (PMA) Using the partial cDNA clone from rat, we have examined cultured rat aortic smooth muscle cells for expression of message for r-p65mox. We have observed the mRNA for rin these cells. It has been previously reported (Griendling et al. (1994) Circ. Res. 74, 1141-1148; Fukui et al.

(1997) Circ. Res. 80, 45-51; Ushio-Fukai et al. (1996) J. Biol.

Chem. 271, 23317-23321) that in vitro or in vivo treatment with angiotensin II (All) is a growth stimulus for vascular smooth muscle cells, and that AII induces increased superoxide generation in these cells. Platelet-derived growth factor (PDGF) and PMA are proliferative signals for vascular smooth muscle cells. We observed that the mRNA for r-p65mox was induced approximately 2-3 fold by angiotensin II (100 nM), WO 00/28031 PCT/US99/26592 54 corresponding to the increased level of superoxide generation.

Thus, the increased superoxide generation in these cells correlates with increased expression of the mRNA for this enzyme. The mRNA for r-p65mox also increased 2 or more fold in response to the growth stimulus PDGF (20 ng/ml), and 2-3 fold in response to PMA. Quantitation by densitometry revealed that rat moxl message was induced nearly 4-fold at the 6 and 12 hour time points in response to PDGF, and about 2fold at the 12 hour time point in response to All. 28S RNA was used as a control for RNA recovery.

EXAMPLE 14 Antibodies to Fragments of Human (h)-p65mox (SEQ ID NO:2) Polyclonal antibodies were raised in rabbits against the C-terminal half of h-p65mox (residues 233 through 564, SEQ ID NO:23) which is predicted to fold into a cytosolic domain containing FAD and the NADPH or NADH binding site. This domain was expressed in E. coli as an N-terminal GST-fusion protein and was purified on glutathione agarose by standard methods. Two antipeptide antibodies were also made against h-p65mox (residues 243-256, referred to as Peptide A, SEQ ID NO:24) and h-65mox (residues 538-551, referred to as Peptide B, SEQ ID NO:25). Peptides were conjugated to keyhole limpet hemocyanin (KLH) using glutaraldehyde.

Antigens were injected into different rabbits initially in complete Freund's adjuvant, and were boosted 4 times with antigen in incomplete Freund's adjuvant at intervals of every three weeks. Approximately 0.5 mg to 1 mg of peptide was administered at each injection. Blood was drawn 1 week after each boost and a terminal bleed was carried out 2 weeks after the final boost. Antibodies to Peptide A and Peptide B were affinity purified by column chromatography through peptide A or peptide B conjugated to Affigel 15 (Bio-Rad, Richmond, CA). 10 mg of peptide was covalently crosslinked to 2 ml of Affigel 15 resin and the gel was washed with 20 ml of binding buffer (20 mM Hepes/NaOH, pH 7.0, 200 mM NaC1, WO 00/28031 PCT/US99/26592 and 0.5 Triton X-100). The remaining functional Nhydrosuccinimide was blocked with 100 .tl of 1 M ethanolamine. After washing with 20 ml of binding buffer, ml of the antiserum was incubated with the pep A-conjugated Affigel 15 resin overnight at 4 0 C. Unbound protein was washed away with 20 ml of binding buffer. Elution of the antibodies from the gel was performed with 6 ml of elution buffer (100 mM glycine/HC1, pH 2.5, 200 mM NaC1, and 0.5% Triton X- 100). The eluate was then neutralized by adding 0.9 ml of 1 M Tris/HC1, pH 8.0. The GST-fusion form of truncated protein (residues 233-566, SEQ ID NO:23) was expressed in E.

coli. Samples (20 jg each) were run on 12 SDS-PAGE either before or 1 or 4 hours after induction with 100 gM IPTG (isopropyl 3-thiogalactoside).

T he extracted proteins were subjected to immunoprobing with affinity purified antiserum to peptide A at a 1:1000 dilution. The detection of antigens was performed using an enhanced chemiluminescence kit (Amersham, Buckinghamshire, UK). The affinity purified antibody to moxl (243-256, SEQ ID NO:24) was used at a dilution of 1:1000 in a Western blot in which a total of 10 ig of protein was added to each lane. The major band observed at 4 hours after IPTG induction corresponded to the size of the GST-moxl expressed in bacteria containing the pGEX-2T vector encoding the GSTmoxl fusion protein.

Example Presence of an NAD(P)H Oxidase in Ras-Transformed Fibroblasts A superoxide-generating NADPH oxidase activity was detected in homogenates from NIH 3T3 cells, and this activity increased about 10-15 fold in Ras-transformed NIH 3T3 cells (Table To establish the stable Ras-transformed cell lines, the DNA for human Ras encoding an activating mutation at amino acid number 12 (Valine, referred to as V12-Ras) was subcloned into BamH1 and EcoR1 sites of pCDNA3 vector WO 00/28031 PCT/US99/26592 56 which has a neomycin resistance gene. V12-Ras in pCDNA3 and empty vector were transfected into NIH 3T3 cells using Lipofectamine Plus (Gibco). 2 X 10 6 cells were maintained with DMEM containing 10% calf serum and transfected with 1 mg of DNA. After 2-days, cells were split and selected with the same medium but containing 1 mg/ml neomycin. Colonies surviving in selection media for 10 to 14 days were subcultured and characterized by immunoblot analysis using antibody against human H-Ras.

The expression of Ras in cells transfected with pcDNA-3 vector alone or in three cell lines transfected with V12-Ras in the same vector was analyzed on a Western blot.

The three cell lines were named V12-Ras-7, V12-Ras-4, and V12-Ras-8. The expression of V12-Ras varied widely among the three cell lines tested. The V12-Ras-4 cell line expressed the highest level of Ras followed by the V12-Ras-8 cell line. The V12-Ras-7 cell line expressed the lowest level of Ras.

Lysates from each of these lines were then prepared and tested for their ability to generate superoxide. For each cell line, cells were washed with cold HANKS' balanced salt solution (HBSS), collected by centrifugation, kept on dry-ice for more than 30 min, and disrupted by suspending in low salt buffer r^ (LSB; 50 mM Tris/HC1, pH 7.5, 1 mM PMSF, and protease cocktail from Sigma) and passing through a syringe needle (18 gauge) ten times. Cell lysates were frozen in dry-ice immediately after determining the protein concentration.

Table 6 shows superoxide generation in the transfected cells measured using the lucigenin luminescence assay. For the assay, 5 gg of cell lysates were incubated with the reaction mixture containing 10 iM lucigenin (luminescent probe) and 100 M NADPH (substrate) in the presence or absence of 100 iM arachidonate in the absence or presence of 100 U of superoxide dismutase (SOD) or 1 pM diphenyleneiodonium (DPI). Luminescence of the reaction mixture was monitored for 0.5 second by LumiCounter (Packard) for four times at 3 second intervals. RLU in Table WO 00/28031 PCT/US99/26592 57 refers to relative luminescence units.

As shown in Table 6, the luminescence was partially inhibited by superoxide dismutase indicating that the signal was due at least in part to the generation of superoxide.

DPI, a known inhibitor of both neutrophil and non-neutrophil NADPH oxidase activities, completely inhibited activity. The generation of superoxide correlated with the expression of Ras in the three cell lines. Thus, oncogenic Ras appears to induce an NADPH-dependent superoxide generating activity that is similar to the activity catalyzed by Table 6 Lg protein no additions plus SOD plus DPI Vector Control 465 154 48 V12-Ras-7 1680 578 39 V12-Ras-4 5975 2128 36 V12-Ras-8 4883 2000 EXAMPLE 16 Molecular Cloning of Another Rat moxl cDNA Called Rat moxlB A rat cDNA library was screened in an effort to identify new rat mox sequences. The library was constructed in a ZAP express lambda phage vector (Stratagene, La Jolla, CA) using RNA isolated from rat vascular smooth muscle cells which had been exposed to 100 nM angiotensin II for 4 hours.

The library was screened using standard blot hybridization techniques with the rat moxl probe described previously.

Fifteen individual clones were obtained that were characterized by PCR and restriction mapping. Two different types of clones were thus identified and representatives of each type were sequenced. A clone of the first type (representative of 13) was found to be similar to the previously identified rat moxl and WO 00/28031 PCT/US99/26592 58 was thus named rat moxlB. Clones of the second type (representative of 2) were incomplete rat mox sequences.

The length of the rat mox B nucleotide sequence is 2619 bp and is listed as SEQ ID NO:41. The single longest 1497 bp open reading frame encompasses nucleotides 362 to 1858. The presence of two in-frame stop codons in the untranslated region at nucleotides 74 and 257 indicates that the full-length coding region has been isolated. Two putative polyadenylation sites are present at positions 2243 and 2592.

Alignment of the rat moxl nucleotide sequence (SEQ ID NO:22) and the rat moxIB nucleotide sequence (SEQ ID NO:41) shows that the two nucleotides sequences are identical except at their 5' ends, suggesting that they may represent two alternatively spliced messages from the same gene. Sequence identity starts at nucleotides 269 and 311, for rat moxl and rat mox B, respectively.

Conceptual translation of the rat mox B nucleotide sequence (SEQ ID NO:41) yields a 499 amino acid sequence with a predicted molecular weight of 58 kDa. This amino acid sequence for rat moxlB protein is shown in SEQ ID NO:42.

Alignment of the deduced amino acid sequences for rat moxl (SEQ ID NO:21) and rat moxlB (SEQ ID NO:42) indicates that rat moxlB is identical to rat moxlA, except for a missing 0 stretch of 64 residues at the N-terminus. Therefore, rat moxlB appears to be a splicing variant derived from the same gene as rat moxl.

EXAMPLE 17 Sequence Analysis and Cloning of the Human Mox2 cDNA (SEQ ID NO:3) Encoding for Production of the Human Mox2 Protein (SEQ ID NO:4) Note that the mox2 protein as described herein, was described in U.S. Provisional Application Serial No. 60/149,332 as mox3.

A blast search was carried out using the sequence of moxl as a query sequence. The sequence identified by this WO 00/28031 PCT/US99/26592 59 search was a sequence present in the GenBank database that contains regions of homology with moxl and gp91phox. The GenBank sequence located in the search was a 90.6 kb sequenced region of human chromosome 6 (6q25.1-26) that was reported as a GenBank direct submission dated February 9, 1999 and given the Accession No. AL031773. Sequencing was carried out as part of the human genome sequencing project by S. Palmer, at Sanger Centre, in Hinxton, Cambridgeshire,

UK.

The GenBank sequence was reported as being similar to "Cytochrome B" and was not reported as having any homology or relation to a mox protein. The sequence contained a theoretical amino acid sequence that was derived by computer using an algorithm that predicted intron/exon boundaries and coding regions. This predicted region contained a 545 amino acid sequence that was 56% identical to moxl and 58% identical to gp9lphox.

In the present invention, based on the GenBank genomic sequence and the homologies described above, several specific primers were designed and used to determine the tissue expression patterns of a novel mox protein, mox2, using Human Multiple Tissue PCR Panels (Clontech, Palo Alto, CA). The primers were as follows: Primer 1: CCTGACAGATGTATTTCACTACCCAG-3' (SEQ ID NO:49); Primer 2: 5'-GGATCGGAGTCACTCCCTTCGCTG-3'

(SEQ

ID NO:50); Primer 3: CTAGAAGCTCTCCTTGTTGTAATAGA-3' (SEQ ID NO:51); Primer 4: 5'-ATGAACACCTCTGGGGTCAGCTGA-3'

(SEQ

ID NO:52). It was determined that mox2 is expressed primarily in fetal tissues, with highest expression in fetal kidney, with expression also seen in fetal liver, fetal lung, fetal brain, fetal spleen and fetal thymus. Among 16 adult tissues tested, mox2 expression was seen in brain, kidney, colon and lung, although levels of expression appeared to be very low.

Additionally, the 5' RACE (RACE Rapid Amplification of cDNA Ends) and 3' RACE techniques were used to complete the sequence of the 5' and 3' regions of mox2.

WO 00/28031 PCT/US99/26592 RACE kit and 3' RACE kit were from Clontech, Palo Alto, CA and are more fully described in Frohman et al. (1988) Proc. Natl. Acad. Sci. USA 85, 8998-9002. The 5' RACE and 3'-RACE techniques were carried out using a human fetal kidney library (Marathon-Ready cDNA library, Cat. #7423-1), using the following specific primers: 5'-RACE: Primer 4: ATGAACACCTCTGGGGTCAGCTGA-3' (SEQ ID NO:53); Primer 5: 5'-GTCCTCTGCAGCATTGTTCCTCTTA-3'

(SEQ

ID NO:54); 3'-RACE: Primer 1: CCTGACAGATGTATTTCACTACCCAG-3' (SEQ ID Primer 2: 5'-GGATCGGAGTCACTCCCTTCGCTG-3'

(SEQ

ID NO:56). The RACE procedures were successful in completing the 5' sequence and in confirming the 3' sequence.

The complete coding sequence of mox2 is shown in SEQ ID NO:2, while the predicted amino acid sequence of mox2 is shown in SEQ ID NO:4.

In comparing the sequences of the present invention to the predicted coding regions of the GenBank sequence, the GenBank sequence did not contain a start codon, appeared to be missing approximately 45 base pairs at the N-terminus, and contained one other major difference in the predicted coding region which could have been due to inaccurate computer prediction of intron/exon boundaries.

EXAMPLE 18 Sequence Analysis and Partial Cloning of the Human Duox2 cDNA (SEQ ID NO:47) Encoding for Production of the Human Duox2 Protein (SEQ ID NO:48) A partial cDNA clone of duox2 was obtained as follows.

A 535-base portion of an expressed sequence tag (EST zc92h03.rl; Genbank accession no. W52750) from human pancreatic islet was identified using the human gp91phox amino-acid sequence as a query in a Blast search. The bacterial strain #595758 containing the EST sequence zc92h03.rl in the pBluescript SK-vector was purchased from ATCC (Rockville, MD). The DNA inserted into the pBluescript SK-vector was WO 00/28031 PCT/US99/26592 61 further sequenced using T7 and T3 vector promoters as well as sequence specific internal primers. The EST encoded 440 amino acids showing a 24.4% identity to gp91phox, including a stop codon corresponding to the C-terminus of gp91phox. RACE was carried out using mRNA obtained from human colon carcinoma cells (CaCo2) and the Marathon cDNA Amplification Kit (ClonTech, Palo Alto). The following genespecific primers were used for this procedure: GAAGTGGTGGGAGGCGAAGACATA-3' (SEQ ID NO:26) and 5'-CCTGTCATACCTGGGACGGTCTGG-3' (SEQ ID NO:27).

The results of the 5'-RACE yielded an additional 2 kilobase of sequenced DNA but this region did not contain the start codon. To complete the sequence of the 5' and 3' regions of duox2, RACE and 3'-RACE were carried out using a human adult pancreas mRNA (Clontech, Palo Alto, CA) with the kit of 5' RACE System for Rapid Amplification of cDNA Ends version 2.0 (Gibco BRL, Gaithersburg, MD). PCR done using the following specific primers resulted in a total predicted amino acid sequence of about 1000 residues: 5'-RACE: Primer 3: 5'-GAGCACAGTGAGATGCCTGTTCAG-3' (SEQ ID NO:28); Primer 4: GGAAGGCAGCAGAGAGCAATGATG-3' (SEQ ID NO:29) (for nested PCR); 3'-RACE Primer 5: ACATCTGCGAGCGGCACTTCCAGA-3' (SEQ ID Primer 6: 5'-AGCTCGTCAACAGGCAGGACCGAGC-3' (SEQ ID NO:31) (for nested PCR).

EXAMPLE 19 Sequence Analysis and Cloning of the Human Duoxl cDNA- (SEQ ID NO:45) Encoding for Production of the Human Duoxl Protein (SEQ ID NO:46) A cDNA clone of duoxl was obtained as follows. A homologous 357-base portion of an expressed sequence tag (EST nr80dl2.sl; Genbank accession no. AA641653) from an invasive human prostate was identified by using the partial WO 00/28031 PCT/US99/26592 62 duox2 predicted amino-acid sequence described above as a query in a Blast search. The bacterial strain #1441736 containing the EST sequence nr80dl2.sl in the pBluescript

SK-

vector was purchased from ATCC (Rockville, MD). The DNA inserted into the pBluescript SK-vector was further sequenced using T7 and T3 vector promoters as well as sequence specific internal primers. The EST insert encoded 673 amino acids with no start or stop codons present. Northern Blot analysis of duoxl indicated the gene was about 5.5 kilobase pairs. To complete the sequence of 5' and 3' regions of duoxl, 5' RACE and 3'-RACE were carried out using a human adult lung mRNA (Clontech, Palo Alto, CA) with the kit of 5' RACE System for Rapid Amplification of cDNA Ends version 2.0 (Gibco BRL, Gaithersburg, MD). The RACE procedure was carried out using the following specific primers: 5'-RACE: Primer 5: GCAGTGCATCCACATCTTCAGCAC-3'(SEQ ID NO:32); Primer 6: 5'-GAGAGCTCTGGAGACACTTGAGTrC-3' (SEQ ID NO:33) (for nested PCR); 3'-RACE Primer 7: CATGTTCTCTCTGGCTGACAAG-3' (SEQ ID NO:34); Primer 8: 5'-CACAATAGCGAGCTCCGCTTCACGC-3'

(SEQ

ID NO:35) (for nested PCR). RACE procedures were successful in completing the 5' sequence and the 3' sequence of duoxl. The open reading frame is approximately 4563 base pairs.

EXAMPLE Tissue Expression of Duoxl and Duox2 Based on the duoxl sequence data, several specific primers were designed (Primer la: GCAGGACATCAACCCTGCACTCTC-3' (SEQ ID NO:36), Primer 2a: 5'-AATGACACTGTACTGGAGGCCACAG-3' (SEQ ID NO:57); Primer 3a: CTGCCATCTACCACACGGATCTGC-3' (SEQ ID NO:58); Primer 4a: 5'-CTTGCCATTCCAAAGCTTCCATGC-3'

(SEQ

ID NO:59) and used these to determine the tissue expression patterns of duoxl using Human Multiple Tissue PCR Panels WO 00/28031 PCT/US99/26592 63 (Clontech, Palo Alto, CA). It was determined that duoxl is expressed primarily in lung, testis, placenta, prostate, pancreas, fetal heart, fetal kidney, fetal liver, fetal lung, fetal skeletal muscle and thymus, with highest expression in adult and fetal lung. Among 16 adult tissues and 8 fetal tissues -tested, duoxl expression in brain, heart, kidney, colon, ovary, thymus, fetal brain and fetal spleen appeared to be low.

Two duox2 specific primers were also used to determine the tissue expression patterns of duox2 using Human Multiple Tissue PCR (polymerase chain reaction) Panels (Clontech, Palo Alto, CA). (Primer lb: GTACAAGTCAGGACAGTGGGTGCG-3' (SEQ ID Primer 2b: 5'-TGGATGATGTCAGCCAGCCACTCA-3'

(SEQ

ID NO:61)). Duox2 is expressed primarily in lung, pancreas, placenta, colon, prostate, testis and fetal tissues, with highest expression in adult lung and fetal tissues. Among 16 adult tissues and 8 fetal tissues tested, duox2 expression in brain, heart, kidney, liver, skeletal muscle, thymus and fetal brain appeared to be low.

EXAMPLE 21 Role of Duoxl and Duox2 in Collagen Crosslinking To investigate a possible role for the human duoxl and duox2, the model organism Caenorhabditis elegans and a new reverse genetic tool, RNA interference (RNAi), were used to "knock out" the homologues of duox in this organism (Fire et al. (1998) Nature 391, 806-811). This technique involved injection of double stranded RNA encoding a segment of Ceduox1 or Ce-duox2 into gonads of C. elegans N2 hermaphrodites. Injected worms were then allowed to lay eggs, and the harvested eggs were allowed to develop and the Fl progeny were scored for phenotypes. This procedure has been documented to "knock-out" the expression of the gene of interest (Fire et al. (1998) Nature 391, 806-811).

In the case of Ce-duoxl and Ce-duox2, the knockout animals resulted in a complex phenotype including WO 00/28031 PCT/US99/26592 64 worms with large superficial blisters, short or "dumpy" worms, worms with locomotion disorders, and worms with retained eggs and/or larvae. Because of the high identity between Ceduoxl and Ce-duox2, three different RNA constructs were predicted to knock out either both genes or Ce-duox2 alone. In all cases, essentially the same group of phenotypes was obtained.

Most or all of these phenotypes had been described previously in C. elegans mutated in the collagen biosynthetic pathway.

C.

elegans has an extracellular structure known as the cuticle, a complex sheath composed largely of cross-linked collagen, which functions as the exoskeleton of the nematode. Crosslinking of collagen in nematodes occurs in part by cross-linking tyrosine residues, and peroxidases such as sea urchin ovoperoxidase and human myeloperoxidase have previously been shown to be capable of carrying out this reaction.

Based upon the similarities of the phenotypes obtained, the Ce-duoxl/2 knockout worms were examined for the presence of dityrosine linkages, using an HPLC methodology (Andersen, S.O. (1966) Acta Physiol. Scand. 66, Suppl. 263-265; Abdelrahim et al. (1997) J. Chromatogr.

B

Biomed. Sci. Appl. 696, 175-182). It was determined that dityrosine linkages, While easily detected in the wild type worms, were almost completely lacking in the knockout worms.

Thus, an inability to catalyze dityrosine cross-linking accounts for the phenotype of C. elegans failing to express Ce-duoxl/2.

These data support the concept that the duox enzymes in higher organisms can probably function in a similar manner to modulate the extracellular milieu, possibly the extracellular matrix and/or the basement membrane.

All patents, publications and abstracts cited above are incorporated herein by reference in their entirety. It should be understood that the foregoing relates only to preferred embodiments of the present invention and that numerous modifications or alterations may be made therein without WO 00/28031 PCT/US99/26592 departing from the spirit and the scope of the present invention as defined in the following claims.

Claims (27)

1. An isolated protein capable of stimulating superoxide production, wherein the protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, or SEQ ID NO:48, a fragment thereof retaining said activity, or a conservative substitution thereof, of less than of the amino acid sequence or fragment thereof wherein the protein, the fragment thereof or the conservative substitution thereof is capable of enzymatic activity of generating reactive oxygen intermediates.

2. An isolated protein capable of stimulating superoxide production, wherein the protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, or SEQ ID NO:48, or a conservative substitution thereof.

3. An isolated protein capable of stimulating superoxide production wherein the protein comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, or SEQ ID NO:48, a deletion thereof or an addition thereto of no more than about 5% of the amino acid sequence, or a conservative substitution thereof, wherein the conservative substitution comprises substitution of a) alanine, serine, or threonine for each other; b) aspartic acid or glutamic acid for each other; c) asparagine or glutamine for each other; d) arginine or lysine for each other; e) isoleucine, leucine, methionine, or valine for each other; and f) phenylalanine, tyrosine, or tryptophan for each other.

4. An isolated protein comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, or SEQ ID NO:48. A polynucleotide comprising a nucleic acid sequence encoding for the protein, the fragment thereof or the conservative substitution thereof, as recited in any one of claims 1 to 4.

6. The polynucleotide sequence of claim 5, wherein the nucleic acid sequence comprises SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, or SEQ ID NO:47.

7. A polynucleotide comprising a nucleic acid sequence comprising SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, or SEQ ID NO:47.

8. A vector, wherein the vector comprises a nucleotide sequence encoding for the protein, the fragment thereof or the conservative substitution thereof, as recited in any one of claims 1 to 4. 9 The vector of claim 8 wherein the nucleotide sequence comprises SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, or SEQ ID NO:47. A vector, wherein the vector comprises a nucleotide sequence comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:22, SEQ ID NO:41, SEQ ID NO:45, or SEQ ID NO:47.

11. A cell containing the vector of claim 8.

12. A cell containing the vector of claim

13. An antibody generated against the protein of any one of claims 1 to 4.

14. An antibody generated against the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:21, SEQ ID NO:42, SEQ ID NO:46, or SEQ ID NO:48. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the protein of any one of claims 1 to 4 in a pharmaceutically acceptable carrier.

16. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the protein of claim 4 in a pharmaceutically acceptable carrier.

17. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the vector of claim 8 in a pharmaceutically acceptable carrier.

18. A method of stimulating superoxide formation comprising administration, in vitro or in vivo, of a composition comprising the vector of claim 9 in a pharmaceutically acceptable carrier.

19. A method for determining activity of a drug or a chemical comprising measuring enzymatic activity of the protein, the fragment thereof or the conservative substitution thereof, as recited in any one of claims 1 to 4, to stimulate superoxide production following administration of the drug or the chemical. A method for determining activity of a drug or a chemical comprising measuring enzymatic activity of the protein recited in claim 4 to stimulate superoxide production following administration of the drug or the chemical.

21. The method of claim 19, wherein the enzymatic activity is NADPH-dependent or NADH-dependent superoxide generation.

22. The method of claim 19, wherein the enzymatic activity is NADPH-dependent or NADH-dependent superoxide generation.

23. A method for determining activity of a drug or a chemical comprising measuring binding of the drug or the chemical to the protein, the fragment thereof or the conservative substitution thereof, as recited in any one of claims 1 to 4.

24. A method for determining activity of a drug or a chemical comprising measuring binding of the drug or the chemical to the protein recited in claim 4. A method for determining activity of a drug or a chemical comprising measuring the activity of the drug or the chemical to modulate proliferative activity of the protein, the fragment thereof or the conservative substitution thereof, as recited in any one of claims 1 to 4. 69

26. A method for determining activity of a drug or a chemical comprising measuring the activity of the drug or the chemical to modulate proliferative activity of the protein recited in claim 4.

27. The method of claim 19, wherein the enzymatic activity is assessed using intact cells, transfected cells or cell lysates thereof.

28. The method of claim 20, wherein the enzymatic activity is assessed using intact cells, transfected cells or cell lysates thereof.

29. An isolated protein according to any one of claims 1 to 4 substantially as hereinbefore described with reference to the examples. A polynucleotide sequence according to claim 5 or claim 7 substantially as hereinbefore described with reference to the examples.

31. A vector according to claim 8 or claim 10 substantially as hereinbefore described with reference to the examples.

32. A cell according to claim 11 or claim 12 substantially as hereinbefore described with reference to the examples.

33. An antibody according to claim 13 or claim 14 substantially as hereinbefore described with reference to the examples.

34. A method according to any one of claims 15-20 and 23-27 substantially as hereinbefore described with reference to the examples.